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NORMALIZING REPRODUCTIVE GENETIC
INNOVATION
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Many societally accepted techniques were quite controversial at inception and for decades
after. For example, historically, dialysis was “unnatural,” vaccination was “the poisoned
quill,” and artificial insemination was akin to adultery. Despite social and cultural
hurdles, the aforementioned medical techniques have today attained overall public
acceptance, permissive legal treatment, and even health insurance coverage in some cases.
Unlike many now-routine treatments like in vitro fertilization (IVF), egg freezing, and
organ transplantation, which flourished without significant governmental intervention, today’s
controversial medical treatments, especially those involving reproductive genetic innovation, face
intense regulatory barriers. Reproductive genetic innovation, which is the combination of IVF
and genetic substitution or modification, is also notable for being accompanied by the continued
call of scientists, regulators, and individuals for a “societal discourse.”
Yet, despite the repeated calls, there is still no clarity as to the concrete structure of a “societal
discourse” or how it could be fostered. This Article adapts the tools of American and
comparative administrative law and public participation to prescribe methods for a societal
consultation on reproductive genetic innovation. Specifically, it draws on notice-and-comment
rulemaking, agency public meetings, the recent rollout of COVID-19 vaccines, the “Consensus
Development Review” used in the normalization of liver transplantation, and citizens’ juries
to provide substantive suggestions for the societal discourse that scientists, commentators, and
federal employees have been requesting for decades.
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INTRODUCTION
Sensationalism is often connected to medical and scientific innovation,
especially as it relates to reproduction.1 In the 1930s, babies created using
artificial insemination by donor sperm were referred to as “eugenic babies.”2
1. June Carbone & Naomi Cahn, Embryo Fundamentalism, 18 WM. & MARY BILL RTS. J. 1015,
1032 (2010) (noting the sensational news coverage that accompanies assisted reproduction).
2. Kara W. Swanson, Adultery by Doctor: Artificial Insemination, 1890-1945, 87 CHI.K ENT L. R EV. 591, 607 (2012).
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Sensationalism has also been criticized as being responsible for the early
stigmatization of babies born as a result of in vitro fertilization (IVF).3 The
term “designer babies” has been used to refer to children who are or will be
selected for sex, eye color, or for traits that could involve genetic
modification, rendering a “superior” child who could form the foundation
for a “brave new world” full of children created through IVF with preordained roles in furtherance of social stability.4 Assisted reproduction
technologies (ARTs) that would involve the creation and storage of embryos,
as well as techniques whose research would involve destroying embryos, like
gene editing, rarely escape the debates about the origins of life, embryo
destruction, and abortion in the United States.5 Further, conversations about
gene editing, especially “reproductive genetic innovation” like human
germline gene editing, often trend towards iterations of a debate related to
fears of the potential enhancement possibilities posed by these new
technologies instead of the potential therapeutic uses. This is despite
potential enhancement targets like athletic ability, height, or intelligence
being hard to manipulate or even define.6
In a New England Journal of Medicine article that has been cited almost 500 times,
physician Eric Cassel noted “[t]he obligation of physicians to relieve human
suffering stretches back into antiquity.”7 Techniques involving reproductive
genetic innovation could alleviate suffering and improve fertility outcomes.8 In
this Article, the term reproductive genetic innovation encompasses cytoplasmic
3. See Alison Murdoch, IVF and The Prevention of Mitochondrial DNA Disease: The Moral Issues,
BIONEWS (May 3, 2011), https://www.bionews.org.uk/page_92949; Carbone & Cahn, supra note 1.
4. See Aldous Huxley, A BRAVE NEW WORLD 6–8 (Harper Collins 2006) (1932); Michael
Sandel, The Case Against Perfection, ATLANTIC (Apr. 2004), https://www.theatlantic.com
/magazine/archive/2004/04/the-case-against-perfection/302927; Eric S. Lander, Brave New
Genome, 373 NEW ENG. J. MED. 5, 5 (2015).
5. See, e.g., Mary Ziegler, Beyond Balancing: Rethinking the Law of Embryo Disposition, 68 AM.
U. L. REV. 515, 518 (2018).
6. See infra Part IV.C. See, e.g., Eric S. Lander, What We Don’t Know, in NAP COMMISSIONED
PAPERS 20, 27 (2015) (observing that traits like height, intelligence, and athletic ability are “very
complex traits—often influenced by hundreds of genes.”).
7. Eric J. Cassell, The Nature of Suffering and the Goals of Medicine, 306 NEW ENG. J. MED.
639, 639 (1982). As of August 2022, Google Scholar notes that Cassell’s 1998 book of the
same title and general subject matter has been cited over 5,000 times. See Eric Cassell,
GOOGLE SCHOLAR, https://scholar.google.com/citations?user=-dNjzPgAAAAJ&hl=en
(last visited Aug. 16, 2022).
8. See NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCIENCE, ETHICS,
AND GOVERNANCE 188 (2017) [hereinafter SCIENCE, ETHICS, AND GOVERNANCE]; NAT’L
ACAD. MED., NAT’L ACAD. SCIS & ROYAL SOC’Y, HERITABLE HUMAN GENOME EDITING 88–
89 (2020) [hereinafter HERITABLE HUMAN GENOME EDITING].
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transfer, mitochondrial transfer, and germline gene or genome editing; although
for many, germline gene editing is considered far more controversial than
cytoplasmic or mitochondrial transfer due to its potential ramifications.9 All of
the aforementioned reproductive genetic innovation techniques combine
genetic modification or substitution with IVF in an effort to improve fertility
outcomes, prevent the inheritance of harmful genetic disease, or both. Also, in
spite of the varying amounts of genetic modification involved with these
individual techniques, all of these promising techniques are now deemed
“experimental” in the United States and are also prohibited by a budget rider
that has been added to every Appropriations Act since 2015, after years of de facto
prohibition by federal administrative agencies.10
In the meantime, scientists and observers have been calling for a
societal consensus on reproductive genetic innovation, especially the
appropriateness of the use of germline, or heritable, gene editing in
certain instances.11 Similarly, federal administrative agency employees,
including the Director of the National Institutes of Health (NIH), have
called for or mentioned societal discourse or consensus. 12 While scientists
9. For technical background on these techniques, see infra Part I.
10. For characterizations of these techniques as “experimental,” see Jason Barritt, Steen
Willadsen, Carol Brenner & Jacques Cohen, Cytoplasmic Transfer in Assisted Reproduction, 7 HUM.
REPROD. UPDATE 428, 433–34 (2001); NAT’L ACADS. SCIS., ENG’G & MED.,
MITOCHONDRIAL REPLACEMENT TECHNIQUES: ETHICAL, SOCIAL, AND POLICY
CONSIDERATIONS 120 (2016) [hereinafter MITOCHONDRIAL REPLACEMENT TECHNIQUES];
David Cyranoski, What CRISPR-Baby Prison Sentences Mean for Research, 577 NATURE 154, 155
(2020). For more on the budget rider, see Russell A. Spivak, I. Glenn Cohen & Eli Y. Adashi,
Germ-line Gene Editing and Congressional Reaction in Context: Learning from Almost 50 Years of
Congressional Reactions to Biomedical Breakthroughs, 30 J.L. & HEALTH 20, 20, 22–23 (citing
Consolidated Appropriations Act of 2016, Pub. L. No. 114-92, § 749, 129 Stat. 2242, 2283
(2015)). For more on the de facto prohibition on techniques involving genetic modification, see
Myrisha S. Lewis, How Subterranean Regulation Hinders Innovation in Assisted Reproductive Technology, 39
CARDOZO L. REV. 1239, 1241–47 (2018) [hereinafter Lewis, Subterranean Regulation].
11. See SCIENCE, ETHICS, AND GOVERNANCE, supra note 8, at 7, 13; David Baltimore, Paul
Berg, Michael Botchan, Dana Carroll, R. Alta Charo, George Church et al., A Prudent Path
Forward for Genomic Engineering and Germline Gene Modification, 348 SCIENCE 36, 37–38 (2015);
Robert K. Naviaux & Keshav K. Singh, Need for Public Debate About Fertility Treatments, 413
NATURE 347, 347 (2001); Eric S. Lander, Françoise Baylis, Feng Zhang, Emmanuelle
Charpentier, Paul Berg, Catherine Bourgain et al., Adopt a Moratorium on Heritable Genome
Editing, 567 NATURE 165, 165 (2019); Broad Scientists and Geneticists Discuss Issues Raised by Clinical
Germline Genome Editing, BROAD INST. (Nov. 26, 2018), https://www.broadinstitute.org/news
/broad-scientists-and-geneticists-discuss-issues-raised-clinical-germline-genome-editing
(referring to statements by Feng Zhang); infra Part II.
12. See Robert M. Califf & Ritu Nalubola, FDA’s Science-Based Approach to Genome Edited
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have continued to meet to discuss the appropriateness of germline gene
editing, the federal administrative state has yet to facilitate that discourse.
Part of the reason for the lack of progress on that societal discourse is that
it remains unclear what the suggested societal discourse would look like, how
it would work, and what it would reasonably be expected to accomplish.
Further, calls for a societal consensus or discourse may substitute for an
intentional delay as structuring a societal discourse might not be a legislative
or regulatory priority, despite scientists’ and policymakers’ calls for one.
Similarly, I do not argue for a domestic or global societal consensus (which is
unlikely), but a societal discourse, at least within the United States is certainly
possible.13 While much of the literature and media coverage has focused on
sensational aspects of gene modifying technologies and the potential slippery
slope from therapy to enhancement, the future American societal discourse
should be one that focuses on “normalization,” meaning the “mainstreaming”
of techniques involving reproductive genetic innovation, instead of
sensationalism.14 In prior articles, I have argued that new techniques that
involve genetic modifications should not be prevented due to the possibility
of future eugenics uses, line crossing, slippery slopes, or other views that stem
from or signify the yuck factor or moral panic that often accompanies genetic

Products, FDA: FDA VOICES (Jan. 18, 2017), http://blogs.fda.gov/fdavoice/index.php/2017
/01/fdas-science-based-approach-to-genome-edited-products/ (“Even as FDA implements
necessary steps for effective regulation to ensure the safety of products, the role of broader,
inclusive public discussion involving multiple constituencies . . . to address the larger societal
considerations should not be overlooked.”); HERITABLE HUMAN GENOME EDITING, supra note
8, at 3 (“Extensive societal dialogue should be undertaken before a country makes a decision
on whether to permit clinical use of heritable human genome editing.”); Francis Collins,
Experts Conclude Heritable Human Genome Editing Not Ready for Clinical Applications, NAT’L INST.
HEALTH: NIH DIR.’S BLOG (Sept. 17, 2020), https://directorsblog.nih.gov/2020/09
/17/experts-conclude-heritable-human-genome-editing-not-ready-for-clinical-applications/.
13. Currently, experts (including scientists who have developed germline gene editing
technologies) cannot come to a consensus on whether there should be a moratorium on these
techniques. See, e.g., Bryan Cwik, Revising, Correcting, and Transferring Genes, AM. J. BIOETHICS,
Aug. 2020, at 7, 9–10 (contrasting various positions of scientists, bioethicists, and nongovernmental organizations on the future legal treatment of germline gene editing, whether it
should continue, and at what pace innovation should occur); Lander et al., supra note 11, at
167 (calling for “broad societal consensus” before any “clinical germline editing”); see also Eli
Y. Adashi, Michael M. Burgess, Simon Burall, I. Glenn Cohen, Leonard M. Fleck, John
Harris et al., Heritable Human Genome Editing: The Public Engagement Imperative, 3 CRISPR J. 434,
434–37 (2020).
14. The term “enhancement,” which is often mentioned as a possible outcome of
reproductive genetic innovation, is not clearly defined. See discussion infra Part IV.C.
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modification.15 This Article builds on that argument by identifying useful
public consultation tools that could shift the discourse related to these
techniques from one that focuses on sensationalism, social opposition, or
fear to one that focuses on medical practice.
This Article unites the scientific and legal literatures by linking scientists’ calls
for a societal discourse with administrative legal structures that could be adapted
to create that discourse.16 The Article also highlights how reproductive genetic
innovation upends some common critiques that administrative law and public
engagement hinder innovation, as it appears a discourse may be critical to
moving reproductive genetic innovation techniques forward.17 Further, there is
a literature on the value of deliberative or participatory democracy, which this
article applies to a potential future discourse on reproductive genetic

15. See Myrisha S. Lewis, Is Germline Gene Editing Exceptional?, 51 SETON HALL L. REV. 735,
735 (2021) [hereinafter Lewis, Is Germline Gene Editing Exceptional?]; Myrisha S. Lewis, How
Analogizing Socio-Legal Responses to Organ Transplantation Can Further the Legalization of Reproductive
Genetic Innovation, 74 SMU L. REV. 665 (2021) [hereinafter Lewis, Socio-Legal Responses]; Charles
W. Schmidt, The Yuck Factor: When Disgust Meets Discovery, 116 ENV’T. HEALTH PERSPS. A524,
A525 (2008) (“Generally speaking, ‘yuck factor’ has become a catchall phrase to describe
technophobic sentiments that vary by what triggers them.”). For more information on the
term “eugenics” and how it has developed over time, see Seema Mohapatra, Politically Correct
Eugenics, 12 FIU L. REV. 51, 53–58 (2016) (citing FRANCIS GALTON, INQUIRIES INTO HUMAN
FACULTY AND ITS DEVELOPMENT 17 n.1 (Gavan Tredoux ed., 2d ed. 1907),
http://galton.org/books/human-faculty/text/galton-1883-human-faculty-v4.pdf.);
Sonia
M. Suter, A Brave New World of Designer Babies?, 22 BERKELEY TECH. L.J. 897, 902–05 (2007);
Osagie K. Obasogie, More Than Love: Eugenics and the Future of Loving v. Virginia, 86 FORDHAM
L. REV. 2795, 2796–99 (2018); Julia Mahoney & Gil Siegal, Beyond Nature? Genomic Modification
and the Future of Humanity, 81 LAW & CONTEMP. PROBS 195, 208 (2018) (“The most emotionally
charged criticism of heritable genome editing is that it threatens to usher in a new era of
‘eugenics.’” (citation omitted)).
16. See Baltimore et al. supra note 11, at 37 (“Given these rapid developments [in
CRISPR-Cas9 technology, a technology which could be used for germline gene editing], it
would be wise to begin a discussion that bridges the research community, relevant industries,
medical centers, regulatory bodies, and the public to explore responsible uses of this
technology.”); Edward Lanphier, Fyodor Urnov, Sarah Ehlen Haecker, Michael Werner &
Joanna Smolenski, Don’t Edit the Human Germ Line, 519 NATURE 410, 411 (2015); Broad Scientists
and Geneticists Discuss Issues Raised by Clinical Germline Genome Editing, BROAD INST. (Nov. 26,
2018), https://www.broadinstitute.org/news/broad-scientists-and-geneticists-discuss-issuesraised-clinical-germline-genome-editing (referring to statements by Feng Zheng).
17. See Mahoney & Siegal, supra note 15, at 212; Nicholas Parrillo, Should the Public Get to
Participate Before Federal Agencies Issue Guidance? An Empirical Study, 71 ADMIN. L. REV. 57, 59
(2019) (observing that processes mandated by the Administrative Procedure Act in connection
with legislative rules are “costly [and] time-consuming”); id. at 102.
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innovation.18 Normatively, the Article identifies, critiques, and adapts several
administrative law tools and also other tools that could facilitate outcomes that
embody the public participatory goals of administrative law and the public
participatory goals of scientists and commentators in the realm of reproductive
genetic innovation. More broadly, the Article contributes to the literature on
the value of process and public deliberation.19
The Article proceeds as follows. Part I begins by providing background
on IVF and reproductive genetic innovation. Part II discusses federal
administrative agency decisions applicable to reproduction, the budget
riders applicable to reproduction and innovation in the United States, the
relationship between calls for public discourse and federal regulation, and
the societal and ethical concerns that can impact administrative agency
and Congressional actions. Part III focuses on regulatory and societal
responses (including sensationalized responses) to commonly accepted
techniques like organ transplantation and vaccination and more societally
and legally contested techniques like assisted reproduction and techniques
involving reproductive genetic innovation. Part IV provides guidance on
how to frame issues of reproductive genetic innovation in the realm of
medical treatment; in doing so, it fosters a hands-off societal approach
instead of one in which members of society, federal agency employees,
and certain legislators impose their own social and religious views on
other individuals’ reproductive decisions without public deliberation. 20
In the United States, the NIH used Consensus Development Review in the
lead up to the addition of organ transplantation to Medicare’s covered
treatments, as were public hearings, which were supported by inquiries (as
18. See Nina A. Mendelson, Foreword: Rulemaking, Democracy, and Torrents of E-mail, 79 GEO.
WASH. L. REV. 1343, 1343 (2011) (citing Mark Seidenfeld, A Civic Republican Justification for the
Bureaucratic State, 105 HARV. L. REV. 1511, 1515 (1992)); Angela M. Banks, Expanding Participation
in Constitution Making: Challenges and Opportunities, 49 WM. & MARY L. REV. 1043, 1046 n.12 (2008);
Nicole Curato, John S. Dryzek, Selen A. Ercan, Carolyn M. Hendriks, & Simon Niemeyer,
Twelve Key Findings in Deliberative Democracy Research, DÆDALUS, Summer 2017 at 28, 28–29.
19. See Giulia Cavaliere, Genome Editing and Assisted Reproduction: Curing Embryos, Society or
Prospective Parents?, 21 MED. HEALTH CARE & PHILOS. 215, 222 (2018); H. Holden Thorp,
Public Debate is Good for Science, 371 SCIENCE 213, 213 (2021); Alan I. Leshner, Public Engagement
with Science, 299 SCIENCE 977, 977 (2003).
20. For more on religious views related to assisted reproductive technology and regulation in
general, see Ariana Eunjung Cha, How Religion Is Coming to Terms with Modern Fertility Methods, WASH.
POST (Apr. 27, 2018), https://www.washingtonpost.com/graphics/2018/national/how-religionis-coming-to-terms-with-modern-fertility-methods/; see also Fertility Issues, BBC, https://www.bbc.
co.uk/bitesize/guides/z2jmyrd/revision/4 (last visited Aug. 16, 2022); NUFFIELD COUNCIL ON
BIOETHICS, GENOME EDITING AND HUMAN REPRODUCTION: SOCIAL AND ETHICAL ISSUES 1, 53
(2018) [hereinafter GENOME EDITING & HUMAN REPRODUCTION].
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conducted by Congressional subcommittees) into the designation of organ
transplantation as “established” instead of experimental.21 Additionally,
administrative law in general involves public outreach procedures, including
notice-and-comment rulemaking and agency meetings where agency employees
interface with the public.22 Other countries, namely the United Kingdom, have
held a societal discourse on the topic of mitochondrial transfer, a reproductive
genetic technique that has been legalized in the United Kingdom but not the
United States.23 Part IV draws on all of these practices and analyzes methods of
public participation that could facilitate a shift from sensationalism or political
arguments to discussions that emphasize medical practice. Ultimately, this
Article draws on these deliberative methods to construct a blueprint for the
societal discourse on reproductive genetic innovation that scientists,
commentators, and patient groups have been requesting for years.
I.

THE SCIENCE OF REPRODUCTIVE GENETIC INNOVATION

The term reproductive genetic innovation, as used in this Article,
encompasses techniques involving the combination of IVF and genetic
substitution or modification, including cytoplasmic transfer, mitochondrial
transfer, and germline genetic modification.24 This Part provides background
on IVF and forms of reproductive genetic innovation.
21. See infra Part IV.C; National Organ Transplant Act: Hearings before the Subcomm. on Health and the
Env’t of the Comm. on Energy and Commerce, 98th Cong. 125 (1983) (statement of Rep. Albert Gore Jr.).
22. See 5 U.S.C. § 553 (2006); Catherine M. Sharkey, Federalism Accountability: “AgencyForcing” Measures, 58 DUKE L. J. 2125, 2163 (2009) (“Notice-and-comment rulemaking is the
means by which federal agencies solicit and incorporate the views of all ‘interested persons’
before issuing final rules.”); Nicholas Bagley, The Procedure Fetish, 118 MICH. L. REV. 345, 368
(2019) (noting that “administrative law is fond of imposing judicially enforceable procedural
rules on agencies to facilitate the ability of outside groups to influence agency decisionmaking,
to monitor agency activities, and to check agency overreach[,]” including notice-andcomment rulemaking); Lars Noah, Doubts About Direct Final Rulemaking, 51 ADMIN. L. REV. 401,
427 (1999) (“According to some commentators, notice-and-comment rulemaking procedures
were designed primarily to facilitate the development of an administrative record in
anticipation for judicial review.”).
23. See infra Part IV.D.2.
24. See supra note 9 and accompanying text. The term “reproductive genetic innovation”
does not draw a line based on heritable or non-heritable genetic modification. Not only is the
definition of heritability contestable for some, but more importantly, the FDA treats all of
these techniques similarly by prohibiting their use without the existence of an investigational
new drug (IND) application. In prior works, I have noted why this regulatory treatment is
surprising in light of the state-based and hands-off treatment of assisted reproductive
technology, including in vitro fertilization, in general. See, e.g., Lewis, Subterranean Regulation,
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A. Assisted Reproduction: In Vitro Fertilization
At least eight million babies have been conceived using IVF, including the
children of celebrities like Chrissy Teigen, Khloe Kardashian, Celine Dion,
and Michelle Obama.25 IVF is a treatment that can be used to help women
who are experiencing fertility limitations conceive children and also to create
embryos for those who may want to use ART for other reasons, such as the
desire to select for embryos that are free of disease or other traits.26
IVF involves the fertilization of an egg with sperm in a laboratory, which is
then implanted into a woman’s uterus with the aim of producing a healthy
pregnancy and child.27 IVF was first used to produce a successful human
pregnancy and birth in 1978 in the United Kingdom.28 Louise Brown, who was
sensationally referred to as the world’s “first test tube baby” in 1978, is now fortyfour years old and has given birth to her own children.29 The first child born as
a result of IVF in the United States has also given birth to her own child.30 In
2010, when awarding Robert G. Edwards the Nobel Prize for his contributions
to the development and use of IVF, the Nobel Prize committee noted that “[h]is
contributions represent a milestone in the development of modern medicine.”31

supra note 10, at 1258–59; Myrisha S. Lewis, Halted Innovation: The Expansion of Federal Jurisdiction
over Medicine and the Human Body, 2018 UTAH L. REV. 1073, 1096, 1101 (2018).
25. See, e.g., Danielle Fowler, 11 Celebrities Who Have Opened Up About Their IVF Experiences: From
Amy Schumer to Michelle Obama, MARIE CLAIRE (Nov. 17, 2020), https://www.marieclaire
.com.au/celebrities-spoken-about-ivf; Susan Scutti, At Least 8 Million IVF Babies Born in 40 Years Since
Historic First, CNN (July 3, 2018, 6:04 AM), https://www.cnn.com/2018/07/03/health
/worldwide-ivf-babies-born-study/index.html.
26. See SCIENCE, ETHICS, AND GOVERNANCE, supra note 8, at 129.
27. In Vitro Fertilization, MAYO CLINIC (Sept. 10, 2021), https://www.mayoclinic.org/
tests-procedures/in-vitro-fertilization/about/pac-20384716.
28. World’s First “Test Tube” Baby Born, HISTORY (July 23, 2020), https://www.history.
com/this-day-in-history/worlds-first-test-tube-baby-born.
29. See id.; Scutti, supra note 25; Cole Moreton, World’s First Test-Tube Baby Louise Brown Has a
Child of Her Own, INDEPENDENT (Jan. 14, 2007, 1:00 AM), https://www.independent.co.uk/lifestyle/health-and-families/health-news/world-s-first-test-tube-baby-louise-brown-has-a-child-ofher-own-432080.html; Ciara Nugent, What It Was Like to Grow Up as the World’s First ‘Test-Tube Baby’,
TIME (July 25, 2018, 5:00 AM), https://time.com/5344145/louise-brown-test-tube-baby.
30. Aina Hunter, U.S. First Test Tube Baby Elizabeth Carr Gives Birth, Tells Her Story, CBS
NEWS (Aug. 9, 2010), https://www.cbsnews.com/news/us-first-test-tube-baby-elizabethcarr-gives-birth-tells-her-story.
31. The Nobel Prize in Physiology or Medicine 2010, NOBEL PRIZE (Oct. 4, 2010),
https://www.nobelprize.org/prizes/medicine/2010/press-release/.
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IVF largely enjoys a hands-off treatment by the U.S. legal system despite
religious and bioethical objections, and safety concerns about the potential
negative impacts of the fertility drugs and ARTs on egg donors, women
implanted with embryos, and children conceived by IVF.32
B. Reproductive Genetic Innovation: Advanced Assisted Reproductive Technologies
In recent years, IVF has been combined with genetic substitution or
modification. This Section provides background on two reproductive
genetic innovation techniques involving the combination of IVF and the
substitution of genetic material: cytoplasmic transfer and mitochondrial
transfer. Previously, I have referred to these techniques collectively as
“advanced assisted reproductive technologies” (AARTs). 33 AARTs
combine IVF with the modification of non-nuclear DNA.34
In short, cells contain a nucleus, which is surrounded by cytoplasm.35
Contained within that cytoplasm are mitochondria, the organelles targeted
in mitochondrial transfer.36 Cytoplasmic, or ooplasmic transfer, was created
for the purpose of improving fertility and can assist individuals who have
trouble conceiving genetically related children.37 On the other hand, most
uses of mitochondrial transfer are intended to prohibit the passage of
devastating genetic conditions, although improved fertility outcomes are also
possible.38 Mitochondrial disease varies in its severity, but mitochondrial
disease affects organs that require the most energy, such as the brain, heart,
and kidneys.39 Mitochondrial transfer and cytoplasmic transfer have been
treated similarly by the regulatory system, as will be detailed in Part II.40
32. See, e.g., Michele Goodwin, Prosecuting the Womb, 76 GEO. WASH. L. REV. 1657, 1693 (2008).
33. See Lewis, Subterranean Regulation, supra note 10, at 1241.
34. Id.
35. See NUFFIELD COUNCIL ON BIOETHICS, NOVEL TECHNIQUES FOR THE PREVENTION
OF MITOCHONDRIAL DNA DISORDERS: AN ETHICAL REVIEW 1, 36–38 (2012) [hereinafter
PREVENTION OF MITOCHONDRIAL DNA DISORDERS].
36. Id. at 18.
37. See Sara Darbandi, Mahsa Darbandi, Hamid Reza Khorram Khorshid, Mohammad
Reza Sadeghi, Ashok Agarwal, Paullav Sengupta et al., Ooplasmic Transfer in Human Oocytes: Efficacy
and Concerns in Assisted Reproduction, 15 REPROD. BIOLOGY & ENDOCRINOLOGY, Oct. 2017, at 1, 5;
PREVENTION OF MITOCHONDRIAL DNA DISORDERS, supra note 35, at 1, 34–38. This Article will
use the term “cytoplasmic transfer.”
38. See PREVENTION OF MITOCHONDRIAL DNA DISORDERS, supra note 35, at 37; Lynsey
Cree & Pasqualino Loi, Mitochondrial Replacement: From Basic Research to Assisted Reproductive Technology
Portfolio Tool—Technicalities and Possible Risks, 21 MOLECULAR HUM. REPROD. 3–4 (2015).
39. PREVENTION OF MITOCHONDRIAL DNA DISORDERS, supra note 35, at 21.
40. See Mauro Cozzolino, Diego Marin, & Giovanni Sisti, New Frontiers in IVF: mtDNA and
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C. Reproductive Genetic Innovation: Heritable Gene Editing
There are two forms of gene editing: gene therapy and germline gene
editing.41 Heritable genetic modification involves germ cells (sperm and egg
cells), whereas somatic modification, or gene therapy, is expected to affect
only an individual’s cells and not the cells of future offspring.42 Somatic cell
gene editing has been used to cure leukemia and treat blindness;43 however,
one significant disadvantage of somatic cell gene editing is that it can only be
used to treat or cure individuals after they are born, as opposed to preventing
the inheritance of certain diseases, some of which are not curable.
Germline gene or genome editing is not included in the aforementioned
category of AART because germline gene editing involves the modification of
nuclear DNA.44 Non-nuclear DNA, in contrast to nuclear DNA, is generally
not associated with a person’s individual identity or characteristics that manifest
in a physical manner like hair and eye color.45 Germline gene editing can
prevent harmful genetic disease from occurring before a child is born. 46 Gene
editing technologies “allow genetic material [including nuclear genetic material]

Autologous Germline Mitochondrial Energy Transfer, REPROD. BIOLOGY & ENDOCRINOLOGY, no.
55, July 2019, at 1, 4–5.
41. SCIENCE, ETHICS, AND GOVERNANCE, supra note 8, at 218.
42. See What is Gene Therapy?, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/vaccines-bl
ood-biologics/cellular-gene-therapy-products/what-gene-therapy (July 25, 2018) (describing
common methods of gene therapy that do not qualify as ART); Somatic Cells, NAT’L HUMAN GENOME
RESEARCH INST., https://www.genome.gov/genetics-glossary/Somatic-Cells (Aug. 18, 2022).
43. See, e.g., Kymriah (tisagenlecleucel), U.S. FOOD & DRUG ADMIN., https://www.fda.gov/vaccinesblood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel (July 7, 2022) (treating
acute lymphoblastic leukemia and relapsed or refractory large B-cell lymphoma); Luxturna, U.S. FOOD
& DRUG ADMIN., https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/
luxturna (June 9, 2022) (treating biallelic RPE65 mutation-associated retinal dystrophy).
44. See Henry T. Greely, CRISPR’d Babies: Human Germline Genome Editing in the ‘He Jiankui
Affair’, 6 J.L. & BIOSCIENCES 111, 115 (2019) (explaining why the author uses the term
“genome” instead of “gene” editing); Rosamund Scott & Stephen Wilkinson, Germline Genetic
Modification and Identity: The Mitochondrial and Nuclear Genomes, 37 OXFORD J. LEGAL STUD. 886,
914 (2017); Bryan Cwik, Revising, Correcting, and Transferring Genes, AM. J. BIOETHICS, Aug. 2020,
at 7, 11–12; MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 10, at 106–08. But see
Erik Parens & Eric Juengst, Inadvertently Crossing the Germ Line, 292 SCIENCE 397, 397 (2001);
Lucía Gómez-Tatay, José M. Hernández-Andreu & Justo Aznar, Mitochondrial Modification
Techniques and Ethical Issues, J. CLINICAL MED., Feb. 2017, at 1, 3.
45. For more on the dispute over the definition of the germline, see Lewis, Socio-Legal
Responses, supra note 15, at 679 n.80.
46. See GENOME EDITING & HUMAN REPRODUCTION, supra note 20, at 21 (2018); infra Part II.
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to be added, removed, or altered at particular locations in the genome.”47
Nevertheless, germline gene editing, as a regulatory matter, is treated similarly
to AARTs, and it raises many of the same bioethical objections and concerns as
AARTs; these include concerns for future persons, disparities and inequality,
and the appropriate role of humans, although objections to germline gene
editing are intensified due to the extent of its modification possibilities.48
Germline gene editing is analyzed from the perspectives of innovation, health
law, Food and Drug Administration (FDA) regulation, and bioethics.49
Pre-implantation genetic testing (PGT), a term which encompasses preimplantation genetic diagnosis (PGD) as well as pre-implantation genetic
screening (PGS), is often suggested as a substitute for germline gene editing;
however, PGT is not perfect, and it can lack the precision and selectivity that
germline gene editing could offer.50 More specifically, PGT cannot screen for
all abnormalities or mitochondrial defects, which can lead to mitochondrial
disease.51 Also, fertility limitations such as advanced maternal age can result in
47. What are Genome Editing and CRISPR-Cas9?, NAT’L LIB. OF MED., https://medlineplus
.gov/genetics/understanding/genomicresearch/genomeediting (Mar. 22, 2022).
48. Some of the bioethical concerns that accompany germline gene editing include
concerns related to the consent of future persons, parental autonomy, health disparities, and
inequalities. See, e.g., Lewis, Is Germline Gene Editing Exceptional?, supra note 15.
49. See, e.g., Paul Enríquez, Editing Humanity: On the Precise Manipulation of DNA in Human
Embryos, 97 N.C. L. REV. 1147, 1156–57 n.27–28 (2019) (providing bioethical scholarship
related to germline gene editing, cloning, and non-heritable gene therapy); Myrisha S. Lewis,
Innovating Federalism in the Life Sciences, 92 TEMP. L. REV. 383 (2020).
50. Recently, the field of reproductive medicine has shifted away from using the term preimplantation genetic diagnosis (PGD) in favor of the broader term, pre-implantation genetic testing
(PGT). See, e. g, Filipa Carvalho, Edith Coonen, Verrle Goossens, Georgia Kookali, Carmen Rubio,
Madelon Meijer-Hoogeveen et al., ESHRE PGT Consortium Good Practice Recommendations for the
Organisation of PGT, HUM. REPROD. OPEN, Feb. 2020, at 1, 2, https://doi.org/10.1093/
hropen/hoaa021 (“The previous terms of preimplantation genetic diagnosis (PGD) and
preimplantation genetic screening (PGS) have been replaced by the term preimplantation genetic
testing (PGT), following a revision of terminology used in infertility care.” (internal citation
ommitted)). See also Joris Robert Vermeesch Thierry Voet & Koenraad Devriendt, Prenatal and PreImplantation Genetic Diagnosis, 17 NATURE REVS. 643, 646, 649 (2016); PGT Q&A, CTR. FOR
ADVANCED REPROD. SERVS., https://www.uconnfertility.com/family-building-programs/gen
etic-testing/pgt-qa/ (last visted Aug. 16); Shoukhrat Mitalipov, Paula Amato, Samuel Parry &
Marni J. Falk, Limitation of Preimplantation Genetic Diagnosis for Mitochondrial DNA Diseases, 7 CELL REPS.
935 (2014); Sozos J. Fasouliotis & Joseph G. Schenker, Preimplantation Genetic Diagnosis Principles and
Ethics, 13 HUM. REPROD. 2238, 2239 (1998).
51. See MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 10, at 44–46, 59; June
Carbone, CRISPR and the Future of Fertility Innovation, 23 SMU SCI. & TECH. L. REV. 31, 36
(2020); Paul R. Brezina & William H. Kutteh, Clinical Applications of Preimplantation Genetic
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fewer embryos that are even suitable for PGT.52 Germline gene editing could
be combined with PGT and used to correct otherwise unsuitable embryos by
removing the traits that harm them.53 This could allay concerns about the
negative impacts of fertility drugs on women as combining PGT with
germline gene editing could minimize the number of rounds of follicle
stimulation and ovarian retrieval that women might need to undergo in
order to use ART in furtherance of a healthy pregnancy. 54
Gene editing, especially germline gene editing, is also accompanied by
several safety concerns, such as the possibility that the technology can also
lead to “off-target” changes which are changes to genetic code that were not
initially intended, which is generally undesirable.55 Scientists who work in the
realm of germline gene editing are largely opposed to using the technology
Testing, BRITISH MED. J., Feb. 2015, at 1, 5; Peter Braude, Susan Pickering, Frances Flinter &
Caroline Mackie Ogilvie, Preimplantation Genetic Diagnosis, 3 NATURE REVS. 941, 942 (2002);
Mitalipov, Amato, Parry & Falk, supra note 50. But see J. Poulton & A.L. Bredenoord, Applying
Pre-Implantation Genetic Diagnosis to mtDNA Diseases: Implications of Scientific Advances, 20
NEUROMUSCULAR DISORDERS 559 (2010); Evrim Unsal, Yasemin Aktas, Oazge Uner, Sarp
Ozcan, Feriba Turhan & Volkan Baltaci, Successful Application of Preimplantation Genetic Diagnosis
for Leigh Syndrome, 90 FERTILITY & STERILITY 2017.e11 (2008).
52. See Filippo Maria Ubaldi, Danilo Cimadomo, Alberto Vaiarelli, Gemma Fabozzi,
Roberta Venturella, Roberta Maggiulli et al., Advanced Maternal Age in IVF: Still a Challenge? The
Present and the Future of Its Treatment, FRONTIERS ENDOCRINOLOGY, Feb. 2019, at 1, 1–2.
53. See Lander, Brave New Genome, supra note 4, at 6; George Q. Daley, Robin LovellBadge & Julie Steffann, After the Storm—A Responsible Path for Genome Editing, 380 NEW ENG. J.
MED. 897, 899 (2019).
54. See Daley, Lovell-Badge & Steffann, supra note 53, at 899; Lindsay Kroener, Dumesic
Daniel & Al-Safi Zain, Use of Fertility Medications and Cancer Risk: A Review and Update, 29 CURRENT
OP. OBSTETRICS & GYNECOLOGY 195, 196 (2017); see, e.g., Marte Myhre Reigstad, Ritsa Storeng,
Tor Age Kyklebust, Nan Birgitte Oldereid, Anne Katerine Omland, Trude Eid Robsahm et al.,
Cancer Risk in Women Treated with Fertility Drugs According to Parity Status: A Registry-Based Cohort Study, 26
CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION 953, 959–60 (2017).
55. For more on on-target mutations resultant from CRISPR gene editing technology,
see Sharon Begley, Potential DNA Damage from CRISPR Has Been ‘Seriously Underestimated,’ Study
Finds, STAT NEWS (July 16, 2018), https://www.statnews.com/2018/07/16/crisprpotential-dna-damage-underestimated/. For more on incomplete editing and unintended
consequences from on-target mutations, see Haoyi Wang & Hui Yang, Gene Edited Babies: What
Went Wrong and What Could Go Wrong, PLOS BIOLOGY, Apr. 30, 2019, at 1, 3. The safety
concerns that would accompany germline gene editing would play a minimal role in a public
consultation, as outlined in Part IV as the public consultation would aim to address social and
moral concerns. Nevertheless, safety concerns would be included in an overview of the
technology, especially when drawing on the “UK case.” See Katrine S. Bosley, Michael
Botchan, Annelien L. Bredenoord, Dana Carroll, R. Alta Charo, Emmanuelle Charpentier et
al., CRISPR Germline Engineering—The Community Speaks, 33 NATURE BIOTECH. 478, 485 (2015).
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before a societal discourse and improvement in the techniques, although there
are “rogue” scientists who have used the technique in embryos, notably Dr.
He Jiankui in China, and others who plan to use the technology.56
II.

MORALITY, SOCIETAL DISCOURSE, AND REGULATION

Reproductive genetic innovation can transform medical practice by truly
moving from treatment to prevention.57 Each of the treatments discussed in
this Article began with controversy, with some involving more controversy
than others. This Part considers the role of sensationalism in the regulatory
system, societal discourse, Congressional responses to reproduction in
general, the bioethical concerns that accompany ART and reproductive
genetic innovation, and scientists’ calls for public consultation in relation to
germline gene editing and other controversial medical techniques.
A. Regulation, Appropriations Riders, and Reproduction
Both administrative agencies and Congress have targeted reproduction for
restrictions. Even though the NIH is a research agency, historically, both the
NIH and the FDA were involved in the regulation and approval of genetic
modification.58 Yet, the NIH announced in the 1980s that “[the Recombinant
56. See R. Alta Charo, Rogues and Regulation of Germline Editing, 380 NEW ENG. J. MED. 976, 976–
78 (2019); Alisa Opar, CRISPR-Edited Babies Arrived, and Regulators Are Still Racing to Catch Up, SCI. AM.
(Jan. 27, 2020), https://www.scientificamerican.com/article/crispr-edited-babies-arrived-and-reg
ulators-are-still-racing-to-catch-up/; Lander et al., supra note 11, at 166 (statement of eighteen
prominent scientists calling for a halt to CRISPR use); Julia Belluz, Is the CRISPR Baby Controversy the
Start of a Terrifying New Chapter in Gene Editing?, VOX (Jan. 22, 2019, 12:40 PM), https://www.vox
.com/science-and-health/2018/11/30/18119589/crispr-gene-editing-he-jiankui.
57. The ability to prevent disease leads to debates over what traits or diseases can or should
be eliminated in society. See, e.g., Elizabeth F. Emens, Framing Disability, 2012 U. ILL. L. REV.
1383, 1395, 1410–18 (2012); Mohapatra, supra note 15, at 69–70; Leon R. Kass, The Wisdom of
Repugnance, NEW REPUBLIC, June 1997, at 17, 24; Radhika Rao, Assisted Reproductive Technology and
the Threat to the Traditional Family, 47 HASTINGS L.J. 951, 952–54 (1996).
58. See, e.g., Who We Are, NAT’L INSTS. HEALTH, https://www.nih.gov/about-nih/whowe-are (last visited Apr. 16, 2022); Francis S. Collins & Scott Gottlieb, The Next Phase of Human
Gene-Therapy Oversight, 379 NEW ENG. J. MED. 1393 (2018); Statement of Policy for Regulating
Biotechnology Products, 51 Fed. Reg. 23,309, 23,311, (June 26, 1986); Points to Consider in
the Design and Submission of Human Somatic-Cell Gene Therapy Protocols, 50 Fed. Reg.
33,463, 33,464 (Aug. 19, 1985); Proposed Action Under the NIH Guidelines for Research
Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines), 80 Fed. Reg.
62,543 (Oct. 16, 2015); Statement on NIH Funding of Research Using Gene-Editing Technologies in
Human Embryos, NAT’L INSTS. HEALTH (Apr. 28, 2015), https://www.nih.gov/aboutnih/who-we-are/nih-director/statements/statement-nih-funding-research-using-geneediting-technologies-human-embryos [hereinafter NIH Director Statement].
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DNA Advisory Committee] and its working group will not at present entertain
proposals for germ line alterations but will consider for approval protocols
involving somatic cell gene therapy.”59 Now, the NIH’s role in the regulation of
genetic modification has been gradually reduced, although the NIH continues
to not fund proposals involving germline gene editing and the FDA continues to
not consider applications involving reproductive genetic innovations.60
Beyond funding, the federal legal system discourages the use of mitochondrial
transfer in the United States as evidenced by the (1) issuance of Untitled Letters
to providers of AARTs, (2) the addition of AARTs and germline gene editing to
the FDA’s Advisory listening techniques which are subject to burdensome
investigational new drug (IND) application requirements, unlike other forms of
ART and natural reproduction.61 Cytoplasmic transfer, which requires IVF,
occurred in the United States before the FDA became aware of it and sent
Untitled Letters informing physicians that if they wished to continue providing
the technique to their patients, they would have to submit an IND application.62
An American company that provided a technique involving mitochondrial
transfer, Ovascience, was targeted by the FDA for regulation; the company
received an Untitled Letter from the FDA and eventually stopped providing
mitochondrial transfer to patients in the United States.63 While scientific
advances in mitochondrial transfer have been made in the United States, they
have been subjected to the same regulatory treatment as cytoplasmic transfer;
thus, the technique is, as a practical matter, unavailable in the United States.64

59. Points to Consider in the Design and Submission of Human Somatic-Cell Gene
Therapy Protocols, 50 Fed. Reg. 33,463, 33,464 (Aug. 19, 1985).
60. See Collins & Gottlieb, supra note 58; NIH Director Statement, supra note 58.
61. See Lewis, Subterranean Regulation, supra note 10.
62. For a comprehensive accounting of the FDA’s targeting of cytoplasmic transfer and similar
forms of assisted reproductive technology involving genetic modification by Letter, see id. at 1241–
47, 1253–62. For the FDA’s perspective on the distinctions between Untitled Letters and Warning
Letters, see U.S. FOOD & DRUG ADMIN., MAN-000007, REGULATORY PROCEDURES MANUAL,
CHAPTER 4: ADVISORY ACTIONS 37 (2022), https://www.fda.gov/media/71878/download.
63. See Lewis, Subterranean Regulation, supra note 10, at 1242–45.
64. See FDA Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products
(HCT/P’s) Product List, FDA Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products
(HCT/P’s) Product List, U.S. FOOD & DRUG ADMIN. (Feb. 1, 2018), https://www.fda.gov/
vaccines-blood-biologics/tissue-tissue-products/fda-regulation-human-cells-tissues-and-cellu
lar-and-tissue-based-products-hctps-product-list (regulating cytoplasmic and mitochondrial
transfer as “human cells used in therapy involving the transfer of genetic material”); see, e.g.,
Brittany Shoot, 3-Parent IVF: Why Isn’t It Available in the United States?, GUARDIAN (Feb. 27, 2015,
8:22 PM), https://www.theguardian.com/sustainable-business/2015/feb/27/3-parent-ivfus-mitochondria-dna-babies.
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Somatic cell gene therapy is legal, used in FDA-approved products, and
results in presumably non-heritable genetic changes. Nonetheless, a budget
rider prevents the FDA from considering INDs involving heritable genetic
modification, which the agency currently interprets as including mitochondrial
transfer and germline gene editing.65 This budget rider, which has been renewed
each fiscal year since it was approved in 2015 (and with little discussion) reads:
None of the funds made available by this Act may be used to notify a sponsor or otherwise
acknowledge receipt of a submission for an exemption for investigational use of a drug or
biological product under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355(i)) or section 351(a)(3) of the Public Health Service Act (42 U.S.C. 262(a)(3))
in research in which a human embryo is intentionally created or modified to include a
heritable genetic modification. Any such submission shall be deemed to have not been
received by the Secretary, and the exemption may not go into effect.66

The budget rider prohibits FDA from using its funds to consider applications
involving “heritable genetic modification,” which the FDA has interpreted to
include not only germline genetic modification (which is clearly heritable), but
also techniques like mitochondrial and cytoplasmic transfer, AART techniques,
which many scholars consider non-heritable genetic modification.67
B. Administrative Agency Decisionmaking and the Role of Societal Discourse
In prior Articles related to certain techniques that fall within the ambit of
reproductive genetic innovation, I have inquired as to what the practical
implication or goal of a societal discourse is. Some groups think that a discourse
should be a prerequisite to the introduction of a technique, whereas others do

65. Consolidated Appropriations Act of 2016, H.R. 2029, 114th Cong. § 749 (2015)
(prohibiting the FDA from considering applications involving heritable genetic modification).
I have previously argued that the idea that AARTs and germline genome editing fall within
the FDA’s jurisdiction is surprising and unsupported. See, e.g., Myrisha S. Lewis, The American
Democratic Deficit in Assisted Reproductive Technology Innovation, 45 AM. J. L.& MED. 130, 131–32,
149–55 (2019) [hereinafter Lewis, The American Democratic Deficit]; Lewis, Subterranean Regulation,
supra note 10, at 1273–74; see also, e.g., Sarah Polcz & Anna Lewis, CRISPR-Cas9 and the NonGermline Non-Controversy, 3 J. L. & BIOSCIENCES 413, 413–14 (2016).
66. H.R. 2029 § 749.
67. See, e.g., Radhika Viswanathan, 3 Biological Parents, 1 Child, and an International Controversy,
VOX (July 28, 2018, 10:00 AM), https://www.vox.com/2018/7/24/17596354/mitochondrialreplacement-therapy-three-parent-baby-controversy (quoting Eli Adashi) (“[Mitochondrial
replacement therapy] can technically be construed as germline modification, so mitochondrial
replacement got swept up into that [Congressional budget] rider. . . . It was caught up in the gene
editing concerns, and I think it’s sort of an unfortunate linkage.”); Eli Y. Adashi & I. Glenn Cohen,
Going Germline: Mitochondrial Replacement as a Guide to Genome Editing, 164 CELL 832, 833 (2016).
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not explain how the debate would be instrumental to regulation.68 While that
answer may not be clear, it is possible that such a discourse could serve to address
the underlying moral and ethical issues that accompany techniques involving
reproductive genetic innovation.69 Moreover, there is a scholarship that focuses
on the value of deliberative democracy as a good in and of itself.70 Beyond the
“good” of deliberative democracy, to the extent that agency employees include
their own moral, religious, or ethical views into agency decisionmaking, what
they think are the moral and ethical views of the American public, or what they
think are the views of the Executive Branch, a discourse could identify those
views, and hopefully make clear when such views might be included in
regulatory decisions (as well as debate whether those views should be included in
regulatory decisions). Thus, in case a societal discourse would serve to further
these techniques beyond their current regulatory standstill, this Article proffers a
potential structure to answer those recurrent calls for a societal discourse.71
The United States has effectively banned reproductive genetic innovation
within its borders but that does not prohibit individuals from traveling
abroad in an effort to skirt that prohibition.72 Nevertheless, for those inclined
to apply such a ban to their activities regardless of location, the current
regulatory sphere largely mirrors the moratorium on germline gene editing
that many have requested.73 While some would like a moratorium forever,
other innovators, like the Broad Institute’s Feng Zhang, would like a
moratorium on the use of germline gene editing of limited duration, such as
for five years, during which time a public discussion would occur.74
68. See GENOME EDITING & HUMAN REPRODUCTION, supra note 20, at 87–88 (2018);
Mahoney & Siegal, supra note 17, at 212.
69. See Alessandro Blasimme, Why Include the Public in Genome Editing Governance Deliberation?, 21
AMA J. ETHICS E1065, E1067 (2019) (“The value of including a plurality of views in democratic
deliberation about controversial science is that it enables dissent and provides opportunities to frame
what’s at stake. Expert committees can succeed in coordinating temporary solutions that avoid
premature research or clinical applications. However, only inclusive deliberation can confer
democratic legitimacy on decisions that can affect the future of humanity.”).
70. Nina A. Mendelson, Rulemaking, Democracy, and Torrents of E-mail, 79 GEO. WASH. L.
REV. 1343, 1343 (2011) (citing Mark Seidenfeld, A Civic Republican Justification for the Bureaucratic
State, 105 HARV. L. REV. 1511, 1515 (1992)).
71. See infra Part IV.
72. Mohapatra, supra note 15, at 64 (“Dr. Zhang was quoted in the press as having said
Mexico was chosen ‘because there are no rules there.’”).
73. Alice Park, Experts Are Calling for a Ban on Gene Editing of Human Embryos. Here’s Why
They’re Worried, TIME (Mar. 13, 2019, 2:22 PM), https://time.com/5550654/crispr-geneediting-human-embryos-ban/.
74. See Pam Belluck, How to Stop Rogue Gene-Editing of Human Embryos?, N.Y. TIMES (Jan.
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Scientists continue to engage in open and public international discussions,
such as the International Gene Editing Summits.75 Commentators and
scientists, including those responsible for the creation of CRISPR-Cas9 gene
editing, have been calling for public consultations related to the technology
in assorted fora.76 For example, the twelve-member Organizing Committee
for the First International Gene Summit released a statement noting that
human gene editing should not proceed until safety and efficacy issues were
resolved and “there is broad societal consensus about the appropriateness
of the proposed application.”77 Yet, with the exception of Human Gene
Editing Summits involving mostly scientists and participants in the field,
such a larger societal consensus has yet to occur. 78
This Article focuses on societal discourse instead of on consensus for two
reasons. First, broad societal consensus in the United States is unlikely.79 The
U.S. has yet to achieve broad societal consensus on far less controversial topics
including IVF, let alone abortion, an issue that lurks beneath many actions
related to reproduction.80 Second, broadening the scope of consensus to include
23, 2019), https://www.nytimes.com/2019/01/23/health/gene-editing-babies-crispr.html;
see also Jon Cohen, The Latest Round in the CRISPR Patent Battle Has an Apparent Victor, but the Fight
Continues, SCIENCE (Sept. 11, 2020), https://www.sciencemag.org/news/2020/09/latest-ro
und-crispr-patent-battle-has-apparent-victor-fight-continues. For more on the patent dispute
related to CRISPR-Cas9, see, for example, id.
75. See, e.g., International Summit on Human Gene Editing, NAT’L ACADS. SCIS., ENG’G & MED.
(2015), https://www.nationalacademies.org/our-work/international-summit-on-human-geneediting; The Second International Summit on Human Gene Editing, NAT’L ACADS. SCIS., ENG’G & MED.
(2018), https://www.nationalacademies.org/our-work/the-second-international-summit-on-hu
man-gene-editing.
76. See, e.g., Daley, Lovell-Badge & Steffann, supra note 53, at 898; Misha Angrist,
Rodolphe Barrangou, Fracnçoise Baylis, Carolyn Brokowski, Gaetan Burgio, Arthur Caplan
et al., Reactions to the National Academies/Royal Society Report on Heritable Human Genome Editing, 3
CRISPR J. 333, 334 (2020) (referencing Jennifer Doudna’s comments); Broad Scientists and
Geneticists Discuss Issues Raised by Clinical Germline Genome Editing, BROAD INST. (Nov. 26, 2018),
https://www.broadinstitute.org/news/broad-scientists-and-geneticists-discuss-issues-raisedclinical-germline-genome-editing (quoting Feng Zheng); Lander et al., supra note 11;
GENOME EDITING & HUMAN REPRODUCTION, supra note 20, at 87–88, 87 n. 299.
77. See New Release, Nat’l Acads. Scis., Eng’g & Med., On Human Gene Editing:
International Summit Statement (Dec. 3, 2015), https://www.nationalacademies.org/news/2015
/12/on-human-gene-editing-international-summit-statement; see also FRANÇOISE BAYLIS,
ALTERED INHERITANCE: CRISPR AND THE ETHICS OF HUMAN GENOME EDITING 8 (2019)
(arguing for societal consensus).
78. See supra note 76 and accompanying text.
79. See GENOME EDITING & HUMAN REPRODUCTION, supra note 20, at 87 n.299
(highlighting the difference between social discourse and consensus).
80. See, e.g., Carbone & Cahn, supra note 1, at 1016–18 (2010).
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other countries presents an even larger challenge; there is nearly endless
literature on international approaches to issues of health care, health insurance
(more broadly), and, more specifically, the legality of reproductive genetic
innovation techniques.81 This Article expects that a global societal consensus,
whatever “consensus” means, on heritable genetic modification—and, relatedly,
non-heritable techniques like cytoplasmic and mitochondrial transfer—is
impossible. As such, this Article focuses on an American public discourse.
There has been ample opportunity to discuss reproductive techniques
involving genetic modification or substitution. Cytoplasmic transfer, for
example, has existed since the 1990s.82 Thus, we have had approximately
thirty years to discuss these techniques, yet we have not done so. Moving
forward, it is worth considering how to facilitate that discussion.
Interestingly, structured societal discussion did not accompany previous
“controversial” techniques that involve DNA transfer, such as blood
donation, bone marrow transplantation, or IVF.
The closest that a federal administrative agency has come to incorporating
public ethical views (instead of the views of its employees) into the regulatory
process related to reproductive genetic innovation was in 2014. In 2014, the
FDA Cellular, Tissue, and Gene Therapies Advisory Committee held a
meeting on the topic of mitochondrial transfer. At that meeting, an FDA
employee stated that, “[t]he FDA recognizes [that there are] moral, ethical,
and social policy issues related to genetic modification of eggs and embryos,
and that these issues have the potential to affect regulatory decisions. However,
these issues are outside of the scope of this advisory committee meeting.”83
81. See, e.g., John A. Robertson, Reproductive Technology in Germany and the United States: An
Essay in Comparative Law and Bioethics, 43 COLUM. J. TRANSNAT’L L. 189, 191–94, 203 (2004);
I. Glenn Cohen, Eli Y. Adashi, Sara Gerke, César Palacios-González, & Vardit Ravitsky, The
Regulation of Mitochondrial Replacement Techniques Around the World, 21 ANN. REV. GENOMICS &
HUM GENETICS 565, 577–79 (2020); Roosa Tikkanen & Melinda K. Abrams, U.S. Health Care
from a Global Perspective, 2019: Higher Spending, Worse Outcomes?, THE COMMONWEALTH FUND:
ISSUE BRIEFS (Jan. 30, 2020), https://www.commonwealthfund.org/publications/issuebriefs/2020/jan/us-health-care-global-perspective-2019; I. Glenn Cohen, Regulating
Reproduction: The Problem with Best Interests, 96 MINN. L. REV. 423, 424–25 (2011); Adashi &
Cohen, supra note 67, 832, 834–35; Sonia M. Suter, Giving in to Baby Markets: Regulation Without
Prohibition, 16 MICH. J. GENDER & L. 217, 262–63 (2009); Carbone & Cahn, supra note 1, at
1034–35, 1049 (2010); Ruqaiijah Yearby, Good Enough to Use for Research, But Not Good Enough to
Benefit From the Results of that Research: Are the Clinical HIV Vaccine Trials in Africa Unjust?, 53
DEPAUL L. REV. 1127, 1129 (2004).
82. See supra Part I; see also Parens & Juengst, supra note 44, at 397 (noting that ooplasmic
transfer, another reproductive technique, emerged in the 1980s).
83. U.S. FOOD & DRUG ADMIN., CTR. FOR BIOLOGICS EVALUATION & RSCH.,
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Since that acknowledgment that “moral, ethical, and social policy issues . . .
[could] affect regulatory decisions[,]” there has been no further identification
of or discussion of those “moral, ethical, and social policy issues.”84
Thus, because the budget rider has stymied the regulatory consideration
of reproductive genetic innovation, these techniques may never obtain
insurance coverage or will face substantial regulatory hurdles in doing so.
Further, both the budget rider and the imposition of IND requirements
substantially curtail the societal discourse.85 In light of the potentially
expansive application of techniques involving genetic modification,
especially germline gene editing, the lack of a societal discourse or regulatory
consideration is particularly impactful as it is possible that agency-specific
views of the appropriateness of a technology are affecting regulation without
potentially useful democratic inputs.86 Arguments in favor of the usefulness
of democratic inputs include (1) if agency employees are going to make
decisions based on their own societal and ethical views, then we should
ensure that they have a more comprehensive accounting of those views, and
(2) if a democratic process includes an acknowledgment that such societal
and ethical views can affect the regulatory process, then the public should
have a clear process to proffer those views in a transparent way.87
While Congress has barely discussed reproductive genetic innovation,
even with the budget rider, scientists and commentators continue to request
a societal discourse.88 This Article is also opposed to budget riders related to
reproductive genetic innovation. First, doing so treats reproductive genetic
innovation differently than natural reproduction. Second, budget riders are
tools that lack the democratic inputs that more substantive legislation
entails.89 Third, while some would argue that a “ban could always be
reversed,” the trajectory of budget riders in the sphere of reproductive
TRANSCRIPT OF CELLULAR, TISSUE, AND GENE THERAPIES ADVISORY COMMITTEE
MEETING #59 13 (2014) [hereinafter MEETING #59 TRANSCRIPT].
84. See id.; Lewis, Subterranean Regulation, supra note 10, at 1271–74.
85. See generally Investigational New Drug Application, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
(describing the types of INDs and explaining the FDA’s application process) (July 20, 2022).
86. Organ transplantation was accompanied by public hearings on the appropriateness
of including the techniques to the list of Medicare-covered procedures. See infra Part IV.D.4.
87. Cf. MEETING #59 TRANSCRIPT, supra note 83, at 13 (acknowledging ethical concerns
but nonetheless limiting the scope of the meeting).
88. See, e.g., supra notes 13–14 and accompanying text; Mary Todd Bergman, Perspectives on Gene
Editing, HARV. GAZETTE (Jan. 9, 2019), https://news.harvard.edu/gazette/story/2019/01
/perspectives-on-gene-editing/ (quoting I. Glenn Cohen on the legal implications of gene editing).
89. See Richard J. Lazarus, Congressional Descent: The Demise of Deliberative Democracy in
Environmental Law, 94 GEO. L.J. 619, 656–57, 660 (2006).
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genetic innovation indicates that they are not so easily reversible. 90
Further, many of the budget riders related to reproduction are funding
restrictions as opposed to restrictions on legality altogether. 91
Many scholars (and some court cases) have highlighted instances where the
FDA has incorporated political or ethical concerns into its decisionmaking
process.92 Some scholars argue that administrative agencies should include
political concerns in their rulemaking or that the FDA specifically should
include ethical views in its decisionmaking.93 Others disagree and argue for
the removal of political and ethical concerns from FDA decisionmaking.94 It

90. Lander, Brave New Genome, supra note 4, at 7.
91. For example, the Hyde Amendment limits abortion access by restraining federal
funding of abortions, not the abortions themselves. See generally Harris v. McRae, 448 U.S.
297 (1980) (allowing states participating in Medicaid to decline to fund medically necessary
abortions “for which federal reimbursement is unavailable under the Hyde Amendment”).
See also NAT’L INST. HEALTH, NIH GUIDELINES FOR RESEARCH INVOLVING RECOMBINANT
OR SYNTHETIC NUCLEIC ACID MOLECULES I-C, I-D (2019); R. Alta Charo, Rogues and
Regulation of Germline Editing, 380 NEW ENG. J. MED. 976, 977–78 (2019) (discussing the
consequences of funding restrictions on the development of IVF and stem cell research);
George J. Annas, Resurrection of a Stem-Cell Funding Barrier—Dickey–Wicker in Court, 363 NEW
ENG. J. OF MED. 1687, 1687–89 (2010); I. Glenn Cohen & Eli Y. Adashi, Human Embryonic
Stem-Cell Research Under Siege—Battle Won But Not the War, 364 NEW ENG. J. OF MED. e48, e48
(2011); JUDITH A. JOHNSON & ERIN D. WILLIAMS, 21 CONG. RSCH. SERV., RL31358, HUMAN
CLONING 1, 3-10 (2006).
92. See generally Lisa Heinzerling, The FDA’s Plan B Fiasco: Lessons for Administrative Law, 102
GEO. L.J. 927 (2014).
93. See, e.g., Dov Fox, Safety, Efficacy, and Authenticity: The Gap Between Ethics and Law in FDA
Decisionmaking, 2005 MICH. ST. L. REV. 1135, 1191–97 (2005); Richard M. Cooper, Science,
Ethics and Economics in FDA Decision-Making: The Legal Framework, 61 FOOD & DRUG L. J. 799,
800–01 (2006); Kathryn A. Watts, Proposing A Place for Politics in Arbitrary and Capricious Review,
119 YALE L.J. 2, 5 (2009). See generally Craig J. Konnoth, Drugs' Other Side Effects, 105 IOWA L.
REV. 171 (2019) (analyzing scenarios in which the FDA considered, ignored, and/or
incorporated political and ethical concerns in rulemaking).
94. See Tummino v. Von Eschenbach, 427 F. Supp. 2d 212, 228 (E.D.N.Y. 2006) (“In
his resignation letter, Dr. Davidoff [an FDA official] stated that ‘I can no longer associate
myself with an organization that is capable of making such an important decision so flagrantly
on the basis of political influence, rather than the scientific and clinical evidence.’” (citation
omitted)). Many have argued for or considered whether the FDA should have more
independence. See, e.g., Dorit R. Reiss, Is it Time For The FDA To Be Independent?, STAT NEWS
(Nov. 30, 2020), https://www.statnews.com/2020/11/03/should-fda-be-independent/;
Robert Califf, Scott Gottleib, Margaret Hamburg, Jane Henney, David Kessler, Mark
McClellan et al., 7 Former FDA Commissioners: The Trump Administration Is Undermining The
Credibility of the FDA, WASH. POST (Sept. 29, 2020, 5:16 PM), https://www.washington
post.com/opinions/2020/09/29/former-fda-commissioners-coronavirus-vaccine-trump/.
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is also possible that one will never be able to remove political, ethical, or social
views from administrative agency decisionmaking. Yet, here, I argue (as I have
argued in other works) for the removal of those views from decisionmaking, or
at the very least, a clear statement of when ethical views impact administrative
agency decisionmaking.95 A societal discourse furthers that goal by offering a
structure for identifying potentially impactful ethical views, increasing
transparency in decisionmaking, and reducing the politicization of science.96
III.

A CONTINUUM OF ACCEPTANCE: FROM SOCIETALLY
ACCEPTED TO SENSATIONALIZED (LEGAL) TREATMENTS

Reproductive genetic innovation techniques are viewed by many as
controversial, and that view, for many, is based not on science but rather on
ethical and moral views that are ultimately incorporated into political
decisions.97 Each of the commonly accepted techniques studied in this Article,
as compared to reproductive genetic innovation, faced early controversy and
skepticism. Notably, the commonly accepted techniques discussed in this Part
generally achieved societal acceptance or consensus after the techniques were
already in use as opposed to before, which thus far appears to be the
prospective path to any legalization of reproductive genetic innovation. The
Article takes a cumulative approach and draws on the legal frameworks and
societal views that have fostered the acceptance of these techniques. This Part
identifies the societal and legal responses that have accompanied each of the
techniques explored in this article respectively: (1) organ transplantation, (2)
vaccination, (3) ART, and (4) reproductive genetic innovation. The treatments
are organized in order from currently most accepted (and less controversial) to
least accepted (and more controversial). Each Section provides the necessary
scientific background on the technique, before moving onto society and the
regulatory system’s reactions to those techniques.

95. See generally Lewis, Subterranean Regulation, supra note 10; Lewis, The American Democratic
Deficit, supra note 65.
96. See Watts, supra note 93, at 33 (advocating for a transparent discourse on political
influences in agency decisionmaking); Konnoth, supra note 93, at 176 (arguing for the FDA to
take a “broader range of concerns and harms” into consideration in its rulemaking).
97. See, e.g., Interview by Christina Lingham with Peter Marks, Dir., Ctr. for Biologics
Evaluation & Rsch., Food & Drug Admin., https://www.triconference.com/transcripts/petermarks-transcript (last visited Aug. 16, 2022) (providing an FDA employee’s characterization of the
area of “heritable genetic modifications” as “a tremendously controversial area.”). For a discussion
of how political, ethical, and social views can affect regulatory decisionmaking in the realm of
techniques involving genetic modification, see generally Lewis, Subterranean Regulation, supra note 10.
For a discussion of the ethical objections to techniques involving genetic modification and their
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In previous works, I have emphasized (1) the four commonalities that exist
between organ transplantation and techniques involving genetic modification;98
(2) the commonalities between FDA-approved gene therapy treatments (similar
to and categorized as pharmaceuticals) and AARTs, like cytoplasmic and
mitochondrial transfer (which fall within the category of reproductive genetic
innovation);99 and (3) AARTs and traditional ART.100 This Article briefly draws
upon those previously explored commonalities before further exploring the
historical and societal development of commonly accepted treatments. Part IV
then draws on the experiences with these medical techniques to propose a path
for the normalization of reproductive genetic innovation.
A. Organ Transplantation
Organ transplantation encompasses procedures that replace defective or nonfunctioning organs with functioning ones.101 Today, public and private
insurance cover organ transplantation.102 Organ transplantation, while
previously accompanied by the yuck factor, is now a technique that has obtained
societal acceptance.103 Examining the early history of organ transplantation
shows that reproductive genetic innovation may also cease to be accompanied
by the yuck factor, or the moral panic that accompanies such innovations early
in their inception, as a technique becomes more effective and more common.104
similarities to other forms of assisted reproductive technology, see Lewis, Is Germline Gene Editing
Exceptional?, supra note 15; see also infra Part III.
98. See Lewis, Socio-Legal Responses, supra note 15, at 690–705.
99. Lewis, Is Germline Gene Editing Exceptional?, supra note 15, at 795–804.
100. Id. at 743, 749–51.
101. The Organ Transplant Process, HEALTH RES. SERVS. ADMIN., https://www.organ
donor.gov/about/process/transplant-process.html (last visited Aug. 16, 2022).
102. See, e.g., Melissa Wong, Note, Coverage for Kidneys: The Intersection of Insurance and Organ
Transplantation, 16 CONN. INS. L.J. 535 (2010); Covering Transplant Costs, UNOS, https://trans
plantliving.org/financing-a-transplant/covering-costs/ (last visited Aug. 16, 2021).
103. See also Charles W. Schmidt, The Yuck Factor: When Disgust Meets Discovery, 116 ENV’T
HEALTH PERSPS. A524, A525 (2008) (“Generally speaking, ‘yuck factor’ has become a catchall
phrase to describe technophobic sentiments that vary by what triggers them.”); Katherine
Purvis, ‘Yuck Factor’ Puts Off Eye Donors, Leaving Vital Transplants at Risk, GUARDIAN (May 7,
2019, 9:00 AM), https://www.theguardian.com/society/2019/may/07/eye-donorstransplant-risk-corneas; Tiffanie Wen, Why Don’t More People Want to Donate Their Organs?,
ATLANTIC (Nov. 10, 2014), https://www.theatlantic.com/health/archive/2014/11/whydont-people-want-to-donate-their-organs/382297/; Claire Stubber & Maggie Kirkman, The
Persistence of the Frankenstein Myth: Organ Transplantation and Surrogate Motherhood, 99 SOUNDINGS:
AN INTERDISCIPLINARY J. 29, 34, 37 (2016).
104. See, e.g., Kieran Healy, Sacred Markets and Secular Ritual in the Organ Transplant Industry, in THE
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Looking at the path through which organ transplantation achieved acceptance
in the U.S. could provide a roadmap for the future acceptance of gene modifying
techniques. In a recent article, I outlined the four commonalities between organ
transplantation and techniques involving genetic modification that weigh in favor
of shifting the discourse: (1) the use of foreign biological material, (2) genetic
transfer, (3) allocation concerns, and (4) controversy at inception.105 Much of the
discourse related to reproductive genetic innovation today is similar to the
rhetoric used in the 1970s to voice opposition to organ transplantation.106
Transplantation is moving further into the issues that have accompanied
reproduction, including debates over whether transplants are therapy or
enhancement and issues related to reproduction. Kidney transplantation
was considered life enhancing for many years before society started to see it
as life-saving.107 Some recent innovations in face, uterine, and penis
transplants have reignited, albeit less intensely, historical controversy related
to organ transplantation.108 Face and penis transplants, which are currently
SOCIOLOGY OF THE ECONOMY 308, 310 (Frank Dobbin ed., 2004); Memorandum from Surgeon
General to the Assistant Secretary for Health, Subject: Liver Transplantation (Feb. 3, 1982),
https://collections.nlm.nih.gov/ext/document/101584930X170/PDF/101584930X170.pdf.
105. Lewis, Socio-Legal Responses, supra note 15, at 690–705.
106. See Pope Warns of Danger in Organ Transplants and Genetic Testing, N.Y. TIMES, Oct. 28,
1980, at A1; Didier A. Mandelbrot & Martha Pavlakis, Living Donor Practices in the United States,
19 ADVANCES IN CHRONIC KIDNEY DISEASE 212, 212 (2012); Fox Butterfield, Massachusetts’
Opposition to Heart Transplant Eases, N.Y. TIMES, Jan. 7, 1984, at 1.7.
107. Todd E. Pesavento, Kidney Transplantation in the Context of Renal Replacement Therapy, 4
CLINICAL J. AM. SOC’Y NEPHROLOGISTS 2035, 2036 (2009).
108. See Arthur Caplan & Duncan Purves, A Quiet Revolution in Organ Transplant Ethics, 43
J. MED. ETHICS 797 (2017) (discussing shifting risks and benefits of transplants aimed at
improving recipients’ quality of life). For more on face transplants, see Brendan Parent,
Informing Donors About Hand and Face Transplants: Time to Update the Uniform Anatomical Gift Act, 10
J. HEALTH & BIOMED. L. 309 (2015) (arguing that the Uniform Anatomical Gift Act should
encourage states to educate people about donating uniquely expressive organs, like hands or
faces). For more on uterine and penile transplants, see Michelle J. Bayefsky & Benjamin E.
Berkman, The Ethics of Allocating Uterine Transplants, 25 CAMBRIDGE Q. HEALTHCARE ETHICS
350, 350, 351 (2016) (discussing uterus transplants ethics); John A. Robertson, Other Women’s
Wombs: Uterus Transplants and Gestational Surrogacy, 3 J.L. BIOSCIENCES 68, 70–71 (2016)
(examining ethical issues, including burden shifting caused by surrogacy); Gennaro Selvaggi
& Sean Aas, New Frontiers in Surgery: The Case of Uterus and Penis Transplantation, in FREEDOM SCI.
RSCH. 71, 77 (Simona Giordano ed., 2019) (noting that penis and uterus transplants are
currently dangerous and expensive, and the benefits do not always outweigh the risks); Arthur
Caplan, Laura L. Kimberly, Brendan Parent, Michael Sosin, & Eduardo Rodriguez, The Ethics
of Penile Transplantation: Preliminary Recommendations, 101 TRANSPLANTATION 1200, 1201–02
(2016) (noting immunosuppressive and psychosocial costs associated with penile
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being pioneered, will raise similar identity-related questions as the other
techniques in this Article.109 For example, using the therapy-enhancement
dichotomy that often surfaces in the context of genetic modification and
historically in organ transplantation, face and penis transplants could be
categorized as life-enhancing as opposed to life-saving although some
physicians would categorize penis transplants as life-saving in light of the
psychological impacts of genitourinary injury.110 At the same time, at a news
conference related to the transplant of “a penis, scrotum, and portion of the
abdominal wall” to a man who had lost his during military service, “the
chairman of plastic and reconstructive surgery at Johns Hopkins, said the
goal of this type of transplant is ‘to restore a person’s sense of identity and
manhood’”; identity is one of the areas of ethical discussion that often arises
in the context of germline gene editing and reproductive genetic innovation,
although certainly in a different manner.111 Compared to many other
developed countries, the American system of regulation pays little
transplantation); Denise Grady, Penis Transplants Being Planned to Help Wounded Troops, N.Y.
TIMES (Dec. 6, 2015) [hereinafter Grady, Wounded Troops], https://www.nytimes.com
/2015/12/07/health/penis-transplants-being-planned-to-heal-troops-hidden-wounds.html.
109. See Changing identity – Face Transplant Ethics, NHS ROYAL FREE LONDON,
https://www.royalfree.nhs.uk/services/services-a-z/plastic-surgery/facial-reconstruction-andface-transplants/changing-identity-face-transplant-ethics/ (last visited Aug. 16, 2022) (“Altered or
changing identity is often the first issue raised when face transplant ethics are discussed with health
professionals, patients and the general public.”); Face Transplant Benefits and Risks, BRIGHAM &
WOMEN’S HOSP., https://www.brighamandwomens.org/surgery/plastic-surgery/restorativesurgery/benefits-and-risks-facial-transplant (last visited Aug. 16, 2022). See generally Jennifer S.
Swindell, Facial Allograft Transplantation, Personal Identity and Subjectivity, 33 J. MED. ETHICS 449 (2007).
110. See Nancy M.P. King, Human Gene-Editing Research: Is the Future Here Yet?, 97 N.C. L. REV.
1051, 1077 (2019) (“Discussion of the similarities and differences among prevention, treatment, and
enhancement is a debate that is older and broader than genetics . . .”); infra Part IV.C; Denise
Grady, Cancer Survivor Receives First Penis Transplant in the United States, N.Y. TIMES (May 16, 2016),
https://www.nytimes.com/2016/05/17/health/thomas-manning-first-penis-transplant-in-us.ht
ml; Dorota J. Hawksworth, Damon S. Cooney, Arthur L. Burnett, Trinity J. Bivalacqua, & Richard
J. Redett, Penile Allotransplantation: Pushing the Limits, 5 EUR. UROLOGY FOCUS 533, 534 (2019); Face
Transplant, MAYO CLINIC, https://www.mayoclinic.org/tests-procedures/face-transplant/about/
pac-20394037 (last visited Aug. 16, 2022); Alexandra Sifferlin & Diane Tsai, What Life Looks Like
After the World’s Most Extensive Face Transplant, TIME (Aug. 25, 2016, 6:30 AM), https://time.com/
4463200/face-transplant-the-first-family-vacation/ (noting that a face transplant recipient had a
50% chance of surviving the procedure); Michael Freeman & Pauline A. Jaoudé, Justifying Surgery’s
Last Taboo: The Ethics of Face Transplants, 33 J. MED. ETHICS 76, 77–79 (2007) (examining identity
challenges encountered by face transplant recipients).
111. See Denise Grady,‘Whole Again’: A Vet Maimed by an I.E.D. Receives a Transplanted Penis,
N.Y. TIMES (Apr. 23, 2018), https://www.nytimes.com/2018/04/23/health/soldier-penistransplant-ied.html; see also Grady, Wounded Troops, supra note 108.
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attention to issues of ART, unlike other countries’ systems like the U.K.’s
which has methods of connecting gamete donors with donor-conceived
children and donor-conceived children with each other. 112 Ultimately,
while the controversies over donor death and other ethical issues in organ
allocation have yet to be resolved, the existence of these controversies
does not prohibit the legality of transplant techniques. 113
B. Vaccination
Some have made the explicit analogy between germline gene editing and
vaccination, like Dr. Dan McArthur, who tweeted during the National
Academies of Sciences and Medicine Germline Gene Editing Summit in
December 2019: “Prediction: my grandchildren will be embryo-screened,
germline-edited. Won’t ‘change what it means to be human’. It’ll be like
vaccination.”114 Vaccines are a recurring part of American and international
society from school-age to adulthood.115 Edward Jenner’s 1796 smallpox
vaccination has been characterized as “the first major vaccine-related
advance.”116 The 1951 Nobel Prize in Physiology or Medicine was awarded to
Max Theiler for his research on Yellow Fever which led to a vaccination.117
Most recently, COVID-19 vaccines based on mRNA technology have received
significant attention.118 Further, states impose vaccination requirements on
school children including common vaccinations against illnesses like tetanus,
diphtheria, pertussis, Hepatitis B, and polio.119 Vaccines have also been cited as
112. See, e.g., Donor Sibling Link (DSL), HUM. FERTILISATION & EMBRYOLOGY AUTH. (Nov. 3,
2020), https://www.hfea.gov.uk/donation/donor-conceived-people-and-their-parents/donor-sibl
ing-link-dsl/; Donor-Conceived People and Their Parents, HUM. FERTILISATION & EMBRYOLOGY AUTH.
(Nov. 3, 2020), https://www.hfea.gov.uk/donation/donor-conceived-people-and-their-parents/.
113. See, e.g., The Urgent Need to Reform the Organ Transplantation System to Secure More Organs for
Waiting, Ailing, and Dying Patients, before the H. Comm. on Oversight & Reform, 117th Cong. (2021); Arthur
Caplan, Bioethics of Organ Transplantation, COLD SPRING HARBOR PERSPS. MED., Mar. 2014, at 4–6.
114. Erika Check Hayden, Should You Edit Your Children’s Genes?, 53 NATURE 402, 405 (2016).
115. For more on vaccine development, see Ana Santos Rutschman, The Vaccine Race in the 21st
Century, 61 ARIZ. L. REV. 729, 734–747 (2019); see also infra notes 124–126 and accompanying text.
116. Angela Desmond & Paul A. Offitt, On the Shoulders of Giants — From Jenner’s Cowpox to
mRNA Covid Vaccines, 385 N. ENGL. J. MED. 1081, 1081 (2021) (citing EDWARD JENNER, AN INQUIRY
INTO THE CAUSES AND EFFECTS OF THE VARIOLAE VACCINAE: A DISEASE DISCOVERED IN SOME
OF THE WESTERN COUNTIES OF ENGLAND, PARTICULARLY GLOUCESTERSHIRE, AND KNOWN BY
THE NAME OF THE COW POX (London: Ashley & Brewer, 1801)).
117. See Max Theiler Facts, THE NOBEL PRIZE, https://www.nobelprize.org/prizes/med
icine/1951/theiler/facts/ (last visited Aug. 16, 2022); Desmond & Offitt, supra note 116, at 1082.
118. Desmond & Offitt, supra note 116, at 1081–82.
119. See Recommended Vaccines Needed by Age, CTRS. FOR DISEASE CONTROL &
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“… occupy[ing] a liminal position between pure treatment and straightforward
enhancement, appearing at first to serve as preventative treatment, but then
forcing us to grapple with the question of where treatment ends and
enhancement begins.”120 Using the terms somatic and germline, the two terms
describing the two types of gene editing, Shawna Benston notes that vaccines
“make up for a somatic deficit” by conferring a non-naturally occurring
protection against disease by including cellular changes.121 Vaccines, similar to
somatic and germline gene editing aim to minimize human suffering although
through different mechanisms: vaccines aim to prevent transmission of diseases,
whereas gene editing aims to “reverse” disease-causing traits or illnesses.122
Thus, the two are certainly not the same, but they do have similar end goals.
Vaccination engenders controversy and “vaccine hesitancy” today with
individuals being resistant to taking vaccines, including the well-covered
trend in which many parents aim to opt out of giving their children vaccines
based on perceptions that vaccines have some connection to autism.123 In
the past, vaccination also engendered controversy based on concerns such as
efficacy, safety, and parental rights.124 Many individuals suffered harms as a
result of vaccinations, which has led to anti-vaccination views for those
affected and those who knew of those adverse reactions.125
PREVENTION, https://www.cdc.gov/vaccines/vpd/vaccines-age.html (Nov. 22, 2016); Y.
Tony Yang & Vicky Debold, A Longitudinal Analysis of the Effect of Nonmedical Exemption Law and
Vaccine Uptake on Vaccine-Targeted Disease Rates, 104 AM. J. PUB. HEALTH 371, 371–73 (2014);
CTRS. FOR DISEASE CONTROL & PREVENTION, GROWING UP WITH VACCINES: WHAT
SHOULD PARENTS KNOW? (2018), https://www.cdc.gov/vaccines/growing/images/global/
CDC-Growing-Up-with-Vaccines.pdf.
120. Shawna Benston, Everything in Moderation, Even Hype: Learning from Vaccine Controversies
to Strike a Balance with CRISPR, 43 J. MED. ETHICS 819, 820 (2017).
121. Id.
122. Id.
123. See id. at 821; Lois A. Weithorn & Dorit Rubinstein Reiss, Providing Adolescents with
Independent and Confidential Access to Childhood Vaccines: A Proposal to Lower the Age of Consent, 52
CONN. L. REV. 771, 773–74 (2020).
124. See Benston, supra note 120, at 820–21; Robert M. Wolfe & Lisa K. Sharp, AntiVaccinationists Past and Present, 325 BRITISH MED. J. 430, 430–32 (2002); James G. Hodge &
Lawrence O. Gostin, School Vaccination Requirements: Historical, Social, and Legal Perspectives, 90 KY.
L.J. 831, 834–35, 846, 876 (2001/2002); Dorit Rubenstein Reiss & Lois A. Weithorn,
Responding to the Childhood Vaccination Crisis: Legal Frameworks and Tools in the Context of Parental
Vaccine Refusal, 63 BUFFALO L. REV. 881, 935, 937–39 (2015); Jason L. Schwartz, New Media,
Old Messages: Themes in the History of Vaccine Hesitancy and Refusal, 14 AMA J. ETHICS 50, 52
(2012); Dorit Rubinstein Reiss, Litigating Alternative Facts: School Vaccine Mandates in the Courts, 21
U. PA. J. CONST. L. 207 (2018).
125. See, e.g., National Vaccine Injury Compensation Program, HEALTH RES. & SERVS. ADMIN. ,
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Current legal analysis of vaccination tends to start with the Supreme
Court case Jacobson v. Massachusetts,126 which upheld the right of the states to
use their police powers to enact compulsory vaccination laws, before
discussing exceptions to those state police powers.127 Before institutions make
vaccines compulsory, for example, they are subject to review and
approval or authorization by the FDA. 128 Safety and effectiveness are the
hallmarks of the FDA’s assessment of medical tools. 129 Often these two
concepts are shown by animal trial data (with the acknowledgment that
safety and efficacy are not absolutely achievable). 130 Part IV.D.5 argues
for a stronger emphasis on animal trials and scientific education related
to reproductive genetic innovation when a public discourse occurs.
C. Assisted Reproductive Technology
Assisted reproductive technology is becoming increasingly prevalent in
American society.131 As early as 1997, Professor Leon Kass—who is known
for, amongst other works, his role as the head of President George W. Bush’s
Bioethics Commission—noted that society had “become accustomed to new
https://www.hrsa.gov/vaccine-compensation/index.html (Nov. 2020); Benston, supra note
120, at 820; Mary S. Holland, Liability for Vaccine Injury: The United States, the European Union, and
the World, 67 EMORY L.J. 415, 419–20 (2018); Efthimios Parasidis, Recalibrating Vaccination Laws,
97 B.U. L. REV. 2153, 2189, 2197–98, 2201, 2204 (2017); Steve P. Calandrillo, Vanishing
Vaccinations: Why Are So Many Americans Opting Out of Vaccinating Their Children?, 37 U. MICH. J.L.
REFORM 353, 389–90 (2004); Reiss & Weithorn, supra note 124, at 886–87.
126. 197 U.S. 11, 35 (1905).
127. See Lindsay F. Wiley & Stephen I. Vladeck, Coronavirus, Civil Liberties, and the Courts:
The Case Against “Suspending” Judicial Review, 133 HARV. L. REV. F. 179, 180–84, 190–94 (2020);
Lindsay F. Wiley, Public Health Law and Science in the Community Mitigation Strategy for Covid-19, 7
J.L. & BIOSCIENCES. 1, 18 (2020); Erwin Chemerinsky & Michele Goodwin, Compulsory
Vaccination Laws Are Constitutional, 110 NW. U.L. REV. 589, 595 (2016). For more on the
controversy that has accompanied compulsory vaccination and vaccination in general, see,
e.g., Schwartz, supra note 124, at 51–52.
128. See, e.g., Emergency Use Authorization for Vaccines Explained, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-ex
plained (Nov. 20, 2020); Understanding the Regulatory Terminology of Potential Preventions and Treatments for
COVID-19, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/consumers/consumer-updates/und
erstanding-regulatory-terminology-potential-preventions-and-treatments-covid-19 (Oct. 20, 2020).
129. See 21 U.S.C. §§ 355(a), 393(b)(2)(B), 360bbb-2(a); 42 U.S.C. § 262(i)(1).
130. See Barbara Evans, Seven Pillars of a New Evidentiary Paradigm: The Food, Drug, and
Cosmetic Act Enters the Genomic Era, 85 NOTRE DAME L. REV. 419, 434–35, 473 (2010).
131. Gretchen Livingston, A Third of U.S. Adults Say They Have Used Fertility Treatments or Know
Someone Who Has, PEW RSCH. CTR. (July 17, 2018), https://www.pewresearch.org/fact-tank/20
18/07/17/a-third-of-u-s-adults-say-they-have-used-fertility-treatments-or-know-someone-who-has/.
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practices in human reproduction,” including IVF, “embryo manipulation,
embryo donation[,]” and surrogacy.132 Today, in addition to insurance
coverage in some states and egg freezing as an employee incentive, there is
an increasing openness in American society to acknowledging the uses of
assisted reproductive technology.133 Further, the consequences of the use of
ART, namely parentage, have been resolved by state family law.134
In the United States, IVF is societally accepted and legal, yet it still elicits
controversy. Assisted reproductive technology generates assorted debates,
including those related to the appropriateness of sex selection or selection of
certain other traits and in some cases, analyses of IVF in general.135
Beyond the baseline legality, acceptance can extend to include societal
encouragement as signified by insurance coverage, employer benefits,
and overall cultural acceptance. 136 Even when a technique has garnered
132. Kass, supra note 57, at 17.
133. See id.; Benjamin J. Peipert, Shelun Tsai, Melissa N. Montoya, Ryan C. Ferrante &
Tarun Jain, Analysis of State Mandated Insurance Coverage for Infertility Treatment and Fertility Preservation in
the United States, 114 FERTILITY & STERILITY E4, E4–E5 (2020); Julia Carpenter, Planning Your
Fertility—With Your Company’s Help, CNN MONEY (Mar. 19, 2018, 4:09 PM), https://money
.cnn.com/2018/03/19/pf/fertility-planning-benefits/index.html; Staci Zaretsky, Top Biglaw Firm
Wows All Employees With New Fertility And Family-Planning Benefits, ABOVE THE LAW (Feb. 3, 2020,
11:15 AM), https://abovethelaw.com/2020/02/top-biglaw-firm-wows-all-employees-with-newfertility-and-family-planning-benefits/?rf=1.
134. See generally JUDITH AREEN, MARC SPINDELMAN & PHILOMILA TSOUKALA, FAMILY
LAW: CASES AND MATERIALS 600–48 (6th ed. 2012); Sonia Bychkov Green, Interstate Intercourse:
How Modern Assisted Reproductive Technologies Challenge the Traditional Realm of Conflicts of Law, 24
WIS. J.L. GENDER & SOC’Y 25, 50, 58–87 (2009).
135. See DOV FOX, BIRTH RIGHTS AND WRONGS: HOW MEDICINE AND TECHNOLOGY
ARE REMAKING REPRODUCTION AND THE LAW 147 (2019) (noting medical reasons for sex
selection); Ethics Committee of the American Society for Reproductive Medicine, Use of
Reproductive Technology for Sex Selection for Nonmedical Reasons, 103 FERTILITY & STERILITY 1418,
1419 (2015); Radhika Rao, Equal Liberty: Assisted Reproductive Technology and Reproductive Equality,
76 GEO. WASH. L. REV. 1457, 1483, 1486–87 (2008); David McCarthy, Why Sex Selection Should
be Legal, 27 J. MED. ETHICS 302, 306 (2001); Obasogie, supra note 15, at 2796–99.
136. See, e.g., Busy Women Lawyers Are Freezing Eggs and Embryos to Manage Careers, YAHOO! (Feb.
27, 2019), https://www.yahoo.com/now/busy-women-lawyers-freezing-eggs-074924236.html.
But see William Levada, Congregation for the Doctrine of the Faith, Instruction Dignitas Personae on Certain
Bioethical Questions, VATICAN (Sept. 8, 2008), https://www.vatican.va/roman_curia/cong
regations/cfaith/documents/rc_con_cfaith_doc_20081208_dignitas-personae_en.html; John M.
Haas, Begotten Not Made: A Catholic View of Reproductive Technology, U.S. CONF. OF CATHOLIC BISHOPS
(1998), http://www.usccb.org/issues-and-action/human-life-and-dignity/reproductive-technolo
gy/begotten-not-made-a-catholic-view-of-reproductive-technology.cfm (last visited Aug. 16, 2022);
Ariana Eunjung Cha, Fertility Frontiers: Gifts from God, WASH. POST (Apr. 27, 2018),
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scientific acceptance, it may not automatically become routine and
commonplace, as illustrated by the general lack of insurance coverage for
fertility treatment, including procedures involving assisted reproductive
technology and fertility preservation by insurance plans. 137
***
Clinical trials, including animal trials, have been a large part of
progress in techniques involving reproductive genetic innovation. 138
Before AARTs like mitochondrial transfer are available for clinical use,
the National Academies of Sciences recommended scientists demonstrate
the “[l]ikelihood of efficacy . . . by preclinical research using in vitro
modeling, animal testing, and testing on human embryos as necessary.” 139
Yet, the National Academies of Science’s recommendations on human
testing are stymied by the Congressional budget rider.140
While ART has generally developed without governmental oversight,
techniques involving genetic modification have been subject to
substantial governmental interference, through the imposition of IND
requirements and Congressional budget riders. 141 This substantial
governmental interference has been largely devoid of democratic
inputs.142 As will be emphasized in Part IV.D.5, physicians developing

https://www.washingtonpost.com/graphics/2018/national/how-religion-is-coming-to-terms-wi
th-modern-fertility-methods/ (noting that “[m]ost major religions have indeed come to tolerate—
and even embrace—IVF, which was originally viewed with equal alarm. But the increasingly
commonplace procedure is still condemned at the highest levels of the Catholic Church.”).
137. For more on why ART is not covered by insurance in some states in the U.S. and
in other countries, even though infertility is recognized as a disease by many, including the
World Health Organization, see Hane Htut Maung, Is Infertility A Disease and Does It Matter?,
33 BIOETHICS 43, 43–45 (2019); Peipert, Tsai, Montoya, Ferrante, Jain, supra note 133
(discussing insurance coverage and ART). There are many unresolved issues that would
surround a discussion of mandating insurance coverage for forms of ART involving genetic
modification and that would fall outside of the scope of this Article.
138. THOMAS STARZL, THE PUZZLE PEOPLE: MEMOIRS OF A TRANSPLANT SURGEON
138, 164 (U. of Pitt. Press 1992) (“The clinical trial of new therapeutic methods is based more
firmly than ever on prior animal experimentation. Virtually all practices in cardiac as well as
in transplantation surgery have been transferred, almost without change, from the laboratory
to the clinical ward or operating room.”).
139. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 10, at 10.
140. Cohen et al., supra note 81, at 442. See Consolidated Appropriations Act of 2016,
Pub. L. No. 114-113, § 749, 129 Stat. 2283 (2015).
141. See supra Part II; R. Alta Charo, Rogues and Regulation of Germline Editing, 380 NEW
ENG. J. MED. 976, 977 (2019); David Adamson, Regulation of Assisted Reproductive Technologies in
the United States, 78 FERTILITY & STERILITY 932, 932 (2002).
142. See, e.g., Lewis, The American Democratic Deficit, supra note 65.
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ART and AARTs have also used extensive animal trials, a hallmark of
pharmaceutical and biologic (vaccine) development.
IV.

NORMALIZATION: REDUCING SENSATIONALISM RELATED TO
REPRODUCTIVE GENETIC INNOVATION

Normalizing reproductive genetic innovation could (1) facilitate the
approval of techniques involving reproductive genetic innovation, (2)
ascertain opposition to reproductive genetic innovation that is based on
morality or politics instead of science or medicine, and (3) serve as part of
scientists’ calls for a public discussion of techniques involving heritable
genetic modification. This discourse is significant to regulation because
political, ethical, and social issues can impact regulation. 143 Having a
discourse on these techniques brings those ethical and social issues to the fore
and could be a first step towards lifting the regulatory standstill that currently
accompanies techniques involving reproductive genetic innovation.
Section A defines normalization. Section B argues that viewing
reproductive genetic techniques through the lenses of commonly accepted
treatments such as vaccinations, organ transplantation, gene therapy, and
to a lesser extent, IVF, instead of the lens of moral panic could facilitate
the use of life-saving gene-modifying techniques by reducing the yuck
factor or moral panic that accompanies these techniques. Section C
builds on the paths to societal acceptance outlined in Part III to address
objections based on enhancement and “slippery slopes.” Section D offers
substantive suggestions for a societal discourse, based on other methods
of public deliberation used in the United States and abroad.

143. See generally Kathryn A. Watts, Proposing A Place for Politics in Arbitrary and Capricious
Review, 119 YALE L.J. 2, 18 (2009) (identifying instances in which administrative agencies,
including agencies that are part of the U.S. Department of Health & Human Services, have
incorporated political influences into their decisionmaking).
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A. Normalization
When I use the term “normalize” as applied to reproductive genetic
innovation, I mean to frame techniques as medical treatments as opposed
to an unnatural occurrences that should be prohibited based on the yuck
factor or sensational reactions that might accompany them. 144 By including
reproductive genetic innovation within the sphere of medical discussion
instead of dystopian fears, political debates, or religious debates, it is
possible to separate social or moral views from scientific views and to have
an informed dialogue about these techniques. 145
The term normalization in this Article is connected to the idea of
medicalization, which is the concept of including naturally occurring natural
phenomena within the ambit of the medical field, but “normalization” goes
beyond the meaning of “medicalization.”146 First, reproductive genetic
innovation is automatically “medicalized,” as the techniques currently fall
within the authority of medical institutions due to the involvement of
physicians or scientists.147 Positive results of medicalization include
improved life expectancy, better medical treatment, and improved quality of
life.148 Medicalization is theoretically a neutral term, although it is often
analyzed negatively; the scholarship on the negative impacts of
medicalization spans many issues, including the impact of medicalization on
the right to an abortion, increased surveillance of women, and forced medical

144. See supra notes 1–6 and accompanying text.
145. See supra Part II.B.
146. See, e.g., Diana C. Parry, “We Wanted a Birth Experience, Not a Medical Experience”:
Exploring Canadian Women’s Use of Midwifery, 29 HEALTH CARE FOR WOMEN INT’L, 784, 785
(2008); Erik Parens, On Good and Bad Forms of Medicalization, 27 BIOETHICS 28, 28 (2013); Rabia
Belt & Doron Dorfman, Reweighing Medical Civil Rights, 72 STAN. L. REV. ONLINE 176, 183
(2020); Allison K. Hoffman, How Medicalization of Civil Rights Could Disappoint, 72 STAN. L. REV.
ONLINE 165, 168–69 (2020).
147. See Parry, supra note 146; Parens, supra note 146, at 28–30; Drew Halfmann,
Recognizing Medicalization and Demedicalization: Discourses, Practices and Identities, 16 HEALTH 186
(2012); Craig Konnoth, Medicalization and the New Civil Rights, 72 STAN. L. REV. 1165 (2020);
Dayna Bowen Matthew, Health and Housing: Altruistic Medicalization of America’s Affordability Crisis,
81 L. & CONTEMP. PROBS. 161, 161–70 (2018); William Sage & Jennifer Laurin, If You Would
Not Criminalize Poverty, Do Not Medicalize It, 46 J.L., MED. & ETHICS 573, 573–80 (2018); Peter
Conrad, The Shifting Engines of Medicalization, 46 J. HEALTH & SOC. BEHAV. 3, 10 (2005);
Michelle Oberman, Motherhood, Abortion, and the Medicalization of Poverty, 46 J. L. MED. & ETHICS
665, 665 (2018); Peter Conrad, Thomas Mackie & Ateev Mehrotra, Estimating the Costs of
Medicalization, 70 SOC. SCI. & MED. 1943, 1943 (2010).
148. See Parry, supra note 146, at 800; Shah Ebrahim, The Medicalisation of Old Age, 324 BMJ
861, 862 (2002); Parens, supra note 146, at 28–29; Conrad, Mackie & Mehrotra, supra note 147.
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treatment of women.149 These concerns about medicalization and
reproduction exist regardless of whether reproduction is natural or
assisted, as would occur with reproductive genetic innovation.
This Article builds on prior scholarship related to the medicalization of
natural occurrences, with a focus on pregnancy and childbirth, and the
cultural and legal acceptance of previously objectionable but now accepted
techniques, in order to reduce the sensationalism that accompanies
reproductive genetic innovation.150 Medicalization can help remove some of
the stigma that accompanies a technique, although it can also increase
stigmatization.151 Thus, the Article draws on the literature related to
medicalization, particularly regarding de-stigmatizing controversial
techniques, in structuring a societal discourse on techniques involving
reproductive genetic innovation. Stigma matters because stigmatized or
sensationalized techniques are often targeted for legal restraints. By focusing
on normalization, this Article emphasizes de-sensationalizing
reproductive genetic innovation and avoids the (often childbirth-focused)
debate on the implications of medicalizing reproduction.

149. See, e.g., Julia Bandini, The Medicalization of Bereavement: (Ab)normal Grief in the DSM-5,
39 DEATH STUD. 347, 347 (2015); Khiara Bridges, Racial Disparities in Maternal Mortality, 95
N.Y.U. L. REV. 1229, 1245 n.57–58 (2020); Michelle Oberman, Mothers and Doctors' Orders:
Unmasking the Doctor's Fiduciary Role in Maternal-Fetal Conflicts, 94 NW. U. L. REV. 451, 452–53
(2000); AM. COLL. OF OBSTETRICIANS & GYNECOLOGISTS, Approaches to Limit Intervention During
Labor and Birth, ACOG Committee Opinion, Num. 766, 133 OBSTETRICS & GYNECOLOGY
e164, e166–67 (2019); Jessica Martucci, Beyond the Nature/Medicine Divide in Maternity Care, 20
AMA J. ETHICS 1168, 1171 (2018); Reva B. Siegel, Roe's Roots: The Women's Rights Claims That
Engendered Roe, 90 B.U. L. REV. 1875, 1878–83 (2010); April L. Cherry, Roe's Legacy: The
Nonconsensual Medical Treatment of Pregnant Women and Implications for Female Citizenship, 6 U. PA. J.
CONST. L. 723, 726, 728–43 (2004); In re A.C., 573 A.2d 1235 (D.C. 1990); Sylvia A. Law,
Childbirth: An Opportunity for Choice that Should Be Supported, 32 N.Y.U. REV. L. & SOC. CHANGE
345, 345–62 (2008); Elizabeth Kukura, Obstetric Violence, 106 GEO. L.J. 721 (2018).
150. See, e.g., Courtney Megan Cahill, Reproduction Reconceived, 101 MINN. L. REV. 617,
654 (2016); Gaia Bernstein, The Socio-Legal Acceptance of New Technologies: A Close Look at Artificial
Insemination, 77 WASH. L. REV. 1035 (2002); Kara Swanson, Adultery by Doctor: Artificial
Insemination, 1890-1945, 87 CHI.-KENT L. REV. 591, 591–95 (2012); Law, supra note 149, at
376 (citing George J. Annas, Homebirth: Autonomy vs. Safety, 8 HASTINGS CTR. REP. 19, (Aug.
19, 1978)); Parry, supra note 146, at 788–90, 795–801.
151. But see INST. MED. NAT’L ACADS., THE HEALTH OF LESBIAN, GAY, BISEXUAL, AND
TRANSGENDER PEOPLE; BUILDING A FOUNDATION FOR BETTER UNDERSTANDING 34 (2011)
(“Nevertheless, after Freud, the division of people into ‘heterosexuals’ and ‘homosexuals’
involved stigmatization of the latter.”).
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B. Sensationalism, Ethics, and the Regulatory System
Several sensational terms, often stemming from science fiction motivated
concerns or yuck-based responses, regularly appear in media coverage of
discussions related to mitochondrial transfer and genome editing.152 The
technique of mitochondrial transfer has commonly been referred to as
“three-parent[IVF],” a characterization that scientists oppose.153 Similarly,
children born as a result of IVF have been subjected to sensational
terminology and media coverage for years.154 While reproductive genetic
innovation techniques are often examined through the lens of bioethics or
ART, this Article adds to that analysis and shows how discussions
surrounding organ and tissue donation and other commonly accepted
medical treatments could be both a useful lens and the basis for a helpful
analogy to use while examining gene-modifying techniques. 155
There are also some differences that support viewing germline gene
editing as less sensational. First, efforts at human germline gene editing focus
on modifying, adding, or deleting human DNA, not animal DNA.156 This
differs from previous attempts in the history of organ transplantation to
transplant animal organs into humans.157 While it is certainly possible that
efforts might shift to xenotransplantation in the future, the potential that
reproductive genetic innovation could one day be used for negative purposes
152. See Marc Thiessen, Gene Editing is Here. It’s an Enormous Threat, FOX NEWS (Nov. 30,
2018, 4:00 AM), https://www.foxnews.com/opinion/marc-thiessen-gene-editing-is-here-itsan-enormous-threat (referring to gene editing as a potential “death blow to the American
dream” due to the potential for wealth-based inequalities in access); Michael Guillen, Sketchy
Genetic Engineering Practices Could Spell the End of the World as We Know It, FOX NEWS (Oct. 19,
2018, 5:08 PM), https://www.foxnews.com/opinion/michael-guillen-its-the-end-of-lifeas-we-know-it; Sarah Gurev, CRISPR in Popular Media: Sensationalism of Germline Editing in
Human Embryos, 10 I NTERSECT 1, 6–8 (2017).
153. See, e.g., Rob Stein, Clinic Claims Success In Making Babies With 3 Parents' DNA, NPR (June
6, 2018, 5:11 AM), https://www.npr.org/sections/health-shots/2018/06/06/615909572/insidethe-ukrainian-clinic-making-3-parent-babies-for-women-who-are-infertile; Rebecca Jacobson,
Why the Term ‘Three-Person Baby’ Makes Doctors Wince, PBS NEWS HOUR (Feb 10, 2015, 2:31 PM),
https://www.pbs.org/newshour/science/term-three-person-baby-makes-doctors-wince;
Françoise Baylis, The Ethics of Creating Children with Three Genetic Parents, 26 REPROD. BIOMEDICINE
ONLINE 531, 531 (2013), https://www.rbmojournal.com/action/showPdf?pii=S14726483%2813%2900132-6 (arguing for the continued use and “legitimacy” of the terms like “‘threeparent embryos’ ‘three-parent babies’ and ‘three-person IVF.’”).
154. See supra notes 1–4 and accompanying text.
155. See supra note 16 and accompanying text.
156. What Are Genome Editing and CRISPR-Cas9?, supra note 47.
157. David K.C. Cooper, Experimental Development of Cardiac Transplantation, 4 BRITISH
M ED. J. 174, 180 (1968).
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should not preclude its use for existing humans and their potential children.
If the safety and efficacy concerns related to germline gene editing are
resolved and only moral and social concerns remain, germline gene editing
and AARTs (which are accompanied by fewer safety and efficacy concerns)
may remain only available to the wealthy, who have the means to access
these techniques abroad or through hard-to-find domestic options.158
C. Normalization Instead of Sensationalism: Therapy Instead of Enhancement
One goal of normalizing techniques involving reproductive genetic
innovation is to move the techniques from experimental to established.
Currently, many controversial techniques have managed to develop in a way
that has permitted them to become established instead of experimental. The
first child born of a cryopreserved egg was born in 1986.159 Decades later, in
2012, the American Society for Reproductive Medicine Practice Committee
removed the experimental label from the description of egg freezing.160
Some concerns related to eugenics or enhancement-based uses pertain
to concerns about the yuck factor that accompanies reproductive genetic
innovation.161 Yet these same societally- and ethically-based concerns
about “unnatural” processes accompanied organ transplantation, which
is now commonly accepted in the United States and around the world. 162
Reducing that yuck factor or moral panic and addressing issues of therapy
versus enhancement could cause legislators and agency staff to be less
opposed to the techniques and reduce the impact of panic-based views,
which can often evince religious opposition, on regulation.

158. See David Orentilcher, Discrimination Out of Dismissiveness: The Example of Infertility, 85
IND. L.J. 143, 181 (2010); see also Tarun Jain, Bernard L. Harlow & Mark D. Hornstein,
Insurance Coverage and Outcomes of In Vitro Fertilization, 347 NEW ENG. J. MED. 661, 661 (2002);
Dorothy E. Roberts, Race and the New Reproduction, 47 HASTINGS L. J. 935, 946 (1996).
159. ETHICS COMMITTEE OF THE AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE,
Planned Oocyte Cryopreservation for Women Seeking to Preserve Future Reproductive Potential: An Ethics
Committee Opinion, 110 FERTILITY & STERILITY 1022, 1022 (2018).
160. Id.
161. See Kass, supra note 57, at 24 (“We do indeed already practice negative eugenic selection,
through genetic screening and prenatal diagnosis.”); Tony McGleenan, Human Gene Therapy and
Slippery Slope Arguments, 21 J. MED. ETHICS 350, 350 (1995); Melissa Murray, Race-ing Roe:
Reproductive Justice, Racial Justice, and the Battle for Roe v. Wade, 134 HARV. L. REV. 2025, 2036–40
(2021). For more on positive and negative eugenics, see Suter, supra note 15, at 905.
162. But see Michele Goodwin, Deconstructing Legislative Consent Law: Organ Taking, Racial
Profiling & Distributive Justice, 6 VA. J.L. & TECH. 2, 8 n.25 (2001).
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Normalization can remove moral concerns from medical decisionmaking.
For example, today, artificial insemination is a technique that individuals
undertake on their own.163 Some no longer consider artificial insemination
a technique of ART due to its simplicity; yet, at its inception, it was extremely
controversial and most assuredly outside of the realm natural reproduction
as were other forms of ART. 164 As a matter of socio-legal acceptance,
“[t]he participation of a doctor did the cultural work of transforming what
some considered a variation of adultery into a treatment for infertility,
that is, ‘sin into therapy.’” 165 Similarly, reproductive genetic innovation
techniques currently would involve physicians. 166
Many individuals avail themselves of medical treatments that others would
reject, such as prenatal testing and selective abortion.167 While ART may face
concrete legal threats in the aftermath of the U.S. Supreme Court’s decision in
163. See, e.g., Lars Noah, Assisted Reproductive Technologies and the Pitfalls of Unregulated Biomedical
Innovation, 55 FLA. L. REV. 603, 608 (2003); Christopher YY. v. Jessica ZZ., 159 A.D.3d 18, 20–21
(N.Y. App. Div. 2018); Steve Almasy, Mother Loses Appeal in Turkey Baster Pregnancy Case, CNN (Apr.
22, 2015, 2:22 AM), https://www.cnn.com/2015/04/21/us/turkey-baster-pregnancy-legalruling; Bruce v. Boardwine, 770 S.E.2d 774, 776–77 (Va. Ct. App. 2015).
164. For various definitions of ART, including differences as to whether artificial
insemination constitutes ART, see Lars Noah, Assisted Reproductive Technologies and the Pitfalls of
Unregulated Biomedical Innovation, 55 FLA. L. REV. 603, 608 n.16 (2003); What is Assisted
Reproductive Technology?, CTRS. FOR DISEASE CONTROL & PREVENTION, https://www.cdc.gov
/art/whatis.html (Oct. 8, 2019); see also Kara W. Swanson, Adultery by Doctor: Artificial
Insemination, 1890–1945, 87 CHI.-KENT L. REV. 591 (2012).
165. Courtney Megan Cahill, Reproduction Reconceived, 101 MINN. L. REV. 617, 654 (2016)
(citing KARA W. SWANSON, BANKING ON THE BODY: THE MARKET IN BLOOD, MILK, AND
SPERM IN MODERN AMERICA 225 (2014)).
166. See supra Part I (describing reproductive genetic innovation, which uses ART and
genetic substitution or modification).
167. See State-Specific Assisted Reproductive Technology Surveillance, CTRS. FOR DISEASE
CONTROL & PREVENTION, https://www.cdc.gov/art/state-specific-surveillance/index.html
(Dec. 27, 2021) (“Nationally, ART accounted for 2.1% of all infants born in the United
States.”); Laura C. Colicchia, Cynthia L. Holland, Jill A. Tarr, Doris M. Rubio, Scott D.
Rothenberger & Judy C. Chang, Patient-Health Care Provider Conversations About Prenatal Genetic
Screening: Recommendation or Personal Choice, 127 OBSTETRICS & GYNECOLOGY 1145, 1145, 1148
(2016) (cohort study finding that “[h]ealth care providers offered genetic screening at 90% of
visits; 78% of women chose genetic screening.”); Marsha Michie, Is Preparation a Good Reason
for Prenatal Genetic Testing? Ethical and Critical Questions, 112 BIRTH DEFECTS RSCH. 332, 332–33
(2020) (estimating that “74% of [U.S.] women with a prenatal diagnosis of Down syndrome—
the most commonly prenatally diagnosed chromosomal condition—choose to terminate.”);
see also Jamie L. Natoli, Deborah L. Ackerman, Suzanne McDermott, & Janice G. Edwards,
Prenatal Diagnosis of Down Syndrome: A Systematic Review of Termination Rates (1995–2011), 32
PRENATAL DIAGNOSIS 142, 142 (2012).
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Dobbs, it is unlikely to be prohibited in the entirety of the United States.168 Some
parents combine pre-implantation genetic testing with ART, while many other
parents reproduce naturally and do not use ART techniques or prenatal testing.169
ART is seemingly in no danger of prohibition. Currently, some parents use PGD
to identify embryos suitable for transplantation, based on parameters provided by
those parents to scientists and physicians who can screen embryos for desirable
and undesirable traits.170 Beyond uses of ART, prenatal testing, and PGD, some
vaccinate their children (and themselves) while many do not.171 All of these
reflect individual decisions about medical techniques and interventions.
While there is a focus on the debate over germline gene editing and the
potential related “slippery slope” from therapy to enhancement, this issue
is not unique to germline gene editing. Instead, the debate over therapy
and enhancement is well engrained in the practice of medicine. The
possibility of enhancement should not prohibit the legality of germline gene
editing. The therapy versus enhancement debate that is cited by some as
a reason not to permit germline gene editing accompanies many forms of
medicine.172 Concerns related to “enhancement” are often the basis for the
slippery slope arguments that lead opponents of gene modifying
technologies to assume that the potential perils of gene modifying
techniques should outweigh more imminent disease-curing uses.173

168. Dobbs v. Jackson Women’s Health Organization, 597 U.S. __ (2022); I. Glenn
Cohen, Melissa Murray & Lawrence O. Gostin, The End of Roe v. Wade and New Legal Frontiers
on the Constitutional Right to Abortion, 328 JAMA 325, 326 (2022).
169. See State-Specific Assisted Reproductive Technology Surveillance, supra note 167; see also Jeani
Chang, Sheree L. Boulet, Gary Jeng, Lisa Flowers & Dmitry M. Kissin, Outcomes of In Vitro
Fertilization with Preimplantation Genetic Diagnosis: An Analysis of the United States Assisted Reproductive
Technology Surveillance Data, 2011–2012, 105 FERTILITY & STERILITY 394, 395 (2016) (reporting
that in 2012 approximately 4% of patients that used IVF used PGD as well); Michie, supra
note 167. For an overview of prenatal testing and PGD, see HENRY T. GREELY, THE END OF
SEX AND THE FUTURE OF HUMAN REPRODUCTION 86–88, 102 (2016).
170. See Chang et al., supra note 168, at 395 (noting increased use of PGD in connection
with IVF); Susannah Baruch, David Kaufman & Kathy L. Hudson, Genetic Testing of Embryos:
Practice and Perspectives of US In Vitro Fertilization Clinics, 89 FERTILITY & STERILITY 1053, 1054
(2008) (estimating that “4%-6% of all IVF cycles in the United States include PGD”).
171. Sara Novak, The Long History of America’s Anti-Vaccination Movement, DISCOVER MAG.
(Nov. 26, 2018, 7:00 PM) https://www.discovermagazine.com/health/the-long-history-ofamericas-anti-vaccination-movement; Allison L. Hargreaves, Glen Nowak, Paula M. Frew,
Alan R. Hinman, Walter A. Orenstein, Judith Mendel et al., Adherence to Timely Vaccinations in
the United States, 145 PEDIATRICS 48, 49, 51 (2020); Schwartz, supra note 124, at 50–52.
172. See, e.g., Bryan Cwik, Revising, Correcting, and Transferring Genes, 20 AM. J. BIOETHICS 7, 7 (2020).
173. See King, supra note 110, at 1077 (discussing the difficulty in defining the term
“enhancement”); Suter, supra note 15, at 933–34; NAT’L HUM. GENOME RSCH. INST., supra note 42.
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A larger discussion of therapy versus enhancement, in addition to
including face transplants and the changed characterization of kidney
transplants, could also focus on tissues such as corneas, which are tissues that
could be categorized as “enhancements,” but whose transplantation
continues in the United States.174 Physicians also use harvested human
tissues in procedures such as knee replacements.175 In the past, corneal
transplants have been accompanied with some of the controversy of organ
transplantation, including controversy related to consent for donation and
the sale of human tissue.176 Further, reminding the public that issues of
therapy and enhancement accompany many existing medical procedures
can reduce the sensationalizing of reproductive genetic innovation.
One potential counterargument is that one does not need to address the
issue of therapy versus enhancement at all. Plastic surgeons offer services
such as the treatment of victims of car accidents and other issues that are
deemed “therapeutic,” while at the same time also offering enhancements
such as face lifts, rhinoplasty, breast augmentation, breast reduction, and
other treatments that are not life-saving.177 Plastic surgery as a specialty is
still available even though it can be used in enhancement. 178 Similarly,
there is a societal approach to organ transplantation and gene therapy
where many individuals accept it, reject it, or do not think about it at all,
but do not aim to prevent it for others. 179 To a lesser extent, some
individuals take this approach to abortion and the use of ART. 180 Some
people use medicines that were developed as therapies for severe diseases
for preventive reasons, such as statins to lower cholesterol. 181
Reproductive genetic innovation could benefit from a similar treatment.
174. Michele Goodwin, Empires of the Flesh: Tissue and Organ Taboos, 60 ALA. L. R EV.
1219, 1223 (2009).
175. Id.
176. Id. at 1223–24.
177. Cosmetic Surgery vs. Plastic Surgery, AM. BD. COSM. SURGERY, https://www.americanboard
cosmeticsurgery.org/patient-resources/cosmetic-surgery-vs-plastic-surgery/ (last visited Aug. 16, 2022).
178. Id.
179. See, e.g., Katie Hafner, Once Science Fiction, Gene Editing Is Now a Looming Reality, N.Y. TIMES
(July 22, 2020), https://www.nytimes.com/2020/07/22/style/crispr-gene-editing-ethics.html.
180. See Karlyn Bowman, Ambivalent on Abortion, FORBES (Jan. 22, 2010, 3:47 PM),
https://www.forbes.com/2010/01/22/abortion-roe-v-wade-anniversary-opinions-colu
mnists-karlyn-bowman.html; see also Chelsea Fortin & Susanne Abele, Increased Length of
Awareness of Assisted Reproductive Technologies Fosters Positive Attitudes and Acceptance Among
Women, 9 I NT ’L J. FERTILITY & STERILITY 452, 459 (2016) (depicting the correlation
between one’s political identity and attitude towards ART).
181 See, e.g., Amy Dockser Marcus, Crispr’s Next Frontier: Treating Common Conditions, WALL
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D. Structuring a Societal Discourse Using Administrative Law
While consensus may never be possible on reproductive genetic
innovation, a discourse is likely worth undertaking. This Article proceeds
based on that assumption even though other options include having (1) no
societal discourse at all, with decisions left to individuals in a permissive
regime, or no one, in the current regulatory standstill; (2) limited discourse
only in connection with issues like governmental funding or insurance
coverage; or (3) discourse only after the technique is societally available or
undergoing larger human clinical trials, as occurred with the innovations
discussed in Part II of the Article. Yet, the current trajectory is toward a
societal discourse before the use of reproductive genetic innovation, at least
in the United States, if the techniques encompassed by the term are ever to
be legalized in the United States. Thus, this Article works within the
confines of the current regulatory expectation even though as a matter of
efficiency, the most expedient method of normalizing reproductive genetic
innovation would be to lift the current budget rider and allow the market
to operate in the way it usually does for medical innovation, whether that
is the hands-off regulation of medical procedures, like with IVF, or the
operation of the federal approval process that reproductive genetic
innovation currently cannot proceed through due to the budget rider. As
the hands-off option seems unlikely and the lifting of the budget rider will
still encounter other hurdles, to include the public, the federal government
likely needs to follow the lead of the United Kingdom, directly facilitating
those discussions about the use and legality of these technologies. 182 Yet,
participation could have disadvantages. For example, those who would
participate in a deliberative mechanism may not represent society at large
but rather extremely interested stakeholders who would not constitute a
cross-section of society.183 While some would consider federal advisory
ST. J. (May 5, 2021, 11:00 AM), https://www.wsj.com/articles/crisprs-next-frontier-treating
-common-conditions-11620226832.
182. See supra Part IV.C; supra note 95 and accompanying text (discussing the possibility that
political and social decisions impact regulatory decisionmaking); infra Part IV.D.4 (discussing the
Congressional hearings that weighed covering certain transplants under Medicare); Richard A.
Rettig, Origins of the Medicare Kidney Disease Entitlement: The Social Security Amendments of 1972, in
BIOMEDICAL POLITICS 176, 181 (Kathi E. Hanna ed., 1991) (“The Gottschalk Committee report, in
1967, sanctioned dialysis and transplantation as established therapies, thus resolving the conflict
between clinicians who wished to treat patients and researchers who thought dialysis experimental.”).
183. See Dorit Rubinstein Reiss, Tailored Participation: Modernizing the APA Rulemaking
Procedures, 12 N.Y.U. J. LEGIS. & PUB. POL'Y 321, 345 (2009); Gary E. Marchant & Andrew
Askland, GM Foods: Potential Public Consultation and Participation Mechanisms, 44 JURIMETRICS J.
99, 123–24 (2003) (discussing bias in the selection and participation of citizen jurors).
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committees as a type of participatory decisionmaking, the same concerns
about bias could apply to federal advisory committees, as the advisory
committee members tend to be experts in the field who would, perhaps, be
better placed as witnesses in a citizens’ jury process instead of as jurors.184
Ultimately, however, based on the trajectory of the societal and regulatory
treatment of reproductive genetic innovation, any negative participation
would simply result in the preservation of the status quo, where traditional
ART in the U.S. is available but ART involving genetic substitution or
modification is not. Consensus-based methods, in which deliberative
public views form a part of regulation, are commonly used in Europe,
Australia, and the U.K.185 Thus, this Article is largely focused on processes
that involve the government, but the government can be a hindrance to
progress and stakeholder conversations, as illustrated by the many medical
innovations that have flourished without federal government involvement,
as well as occurrences outside of the realm of health and medicine, namely
environmental law, where consensus has been used to resolve disputes. 186
1. Inadequacies of Familiar Structures
There are a number of options that can increase public participation in the
scientific process. Referenda and ballot initiatives, like the California ballot
initiatives on stem cell funding, can indicate public perspectives on scientific
matters, although they are not used on a federal level.187 However, referenda
are not seen as deliberative as the only options are “yes” or “no.”188 Surveys,
184. See Marchant & Askland, supra note 183, at 119–20; Matthew D. Adler, Welfare Polls: A
Synthesis, 81 N.Y.U. L. REV. 1875, 1878 (2006) (“A variety of concrete formats have been proposed
for civic republican citizen deliberation, including citizen advisory committees or review panels,
citizen juries, and ‘deliberative polling.’” (citations omitted)); Advisory Committees Give FDA Critical
Advice and the Public a Voice, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/consumers/cons
umer-updates/advisory-committees-give-fda-critical-advice-and-public-voice (Oct. 20, 2020);
FOOD AND DRUG ADMINISTRATION ADVISORY COMMITTEES 88–89, 98 (Richard A. Rettig et al.,
eds., 1992); Stéphane Lavertu & David L. Weimer, Federal Advisory Committees, Policy Expertise, and the
Approval of Drugs and Medical Devices at the FDA, 21 J. PUB. ADMIN. RSCH. & THEORY 211, 212 (2011).
185. Tee Rogers-Hayden & Nick Pidgeon, Reflecting Upon the UK's Citizens' Jury on
Nanotechnologies: Nanojury UK, 3 NANOTECHNOLOGY L. & BUS. 167, 168 (2006).
186. See Karrigan Bork, Governing Nature: Bambi Law in A Wall-E World, 62 B.C. L. REV.
155, 204 (2021) (citing Marc B. Mihaly, Citizen Participation in the Making of Environmental
Decisions: Evolving Obstacles and Potential Solutions Through Partnership with Experts and Agents, 27
PACE ENV’T L. REV. 151, 188 (2010)).
187. See generally Marchant & Askland, supra note 183, at 116 (identifying “Referenda and
Initiatives” as methods of increasing public participation in science); Nidhi Subbaraman,
California’s Vote to Revive Controversial Stem-Cell Institute Sparks Debate, 587 NATURE 535, 535 (2020).
188. Marchant & Askland, supra note 183, at 116.
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community meetings, and focus groups have also been characterized as a
method of increasing the involvement of individuals in government.189
Administrative law is known for its notice-and-comment process, by which
members of the public submit comments on proposed regulations provided
by federal agencies.190 Administrative agencies routinely engage in publicfacing efforts, such as general public meetings.191 Currently, the regulation
of reproductive genetic innovation is centered in budget riders, as of 2016,
so there would be no regulation to discuss and, the Article does not advocate
for those standard administrative law methods such as increased use of
notice-and-comment rulemaking.192
Agency meetings focus on conveying information to the public or
obtaining public comments, so they are inherently less deliberative
because agency employees obtain the views of the public and provide
arguably non-deliberative responses. 193 After the agency responds that it
agrees, disagrees, or notes that comments are out of the scope of the
rulemaking, it often provides scant explanation of its position on the
public comments and does not engage in any meaningful back-and-forth
after its response. 194 Further, the deliberation involved with agency
meetings focuses on the gathering of information from the public and
notice-and-comment processes is less deliberative than the other models
explored in this Article. 195 This Article does not provide an exhaustive

189. Susan Pickard, Citizenship and Consumerism in Health Care: A Critique of Citizens’ Juries,
32 SOC. POL’Y & ADMIN. 226, 229 (1998).
190. 5 U.S.C. § 553 (2006); There is an extensive literature devoted to critiquing and
analyzing the notice-and-comment process. See, e.g., Roni A. Elias, The Legislative History of the
Administrative Procedure Act, 27 FORDHAM ENVT’L L. REV. 207, 219–20 (2016); see TODD
GARVEY, CONG. RSCH. SERV. R41546, A BRIEF OVERVIEW OF RULEMAKING AND JUDICIAL
REVIEW (2017); S. DOC. NO. 248 (1944–46), reprinted in LEGISLATIVE HISTORY OF THE
ADMINISTRATIVE PROCEDURE ACT, 1946, at 18-20 (1946); Parrillo, supra note 17.
191. William R. Sherman, The Deliberation Paradox and Administrative Law, 2015 B.Y.U. L.
REV. 413, 416–17, 443 (2015) (discussing agency meetings).
192. See supra Part II.A; supra Part III.
193 See Sherman, supra note 191, at 451.
194. See Jonathan Weinberg, The Right to be Taken Seriously, 67 U. MIAMI L. REV. 149, 149–
50, 158 (2002) (noting the goal of agency comment response); Parrillo, supra note 17, at 83.
195. See, e.g., Nina A. Mendelson, Rulemaking, Democracy, and Torrents of E-mail, 79 GEO. WASH.
L. REV. 1343, 1363–64 (2011) (“Very frequently, a notice of final rule will note the filing of large
numbers of public comments, but will pass over those comments lightly, saving detailed responses
for more sophisticated or technical comments. In general, rulemaking documents only occasionally
acknowledge the number of lay comments and the sentiments they ex-press; they very rarely appear
to give them any significant weight.” (citations omitted)). This Article focuses on notice-and-

ALR 74.3_LEWIS_481-538.DOCX (DO NOT DELETE)

522

9/6/2022 11:13 AM

ADMINISTRATIVE LAW REVIEW

[74:3

analysis of all potential administrative legal options. For example, in the
realm of bioethics, other scholars have lamented the end of presidential
bioethics commissions, although these commissions were designed for
expert consultation, not solicitation of public input. 196 Nevertheless,
consensus development is often one goal of a bioethics commission. 197
Similarly, the Office of Technology Assessment, a Congressional entity,
existed from 1972 until 1995 and provided guidance to Congress on
emerging technological issues, ranging from e-mail to biomedical
research to nuclear weapons. 198 In 2022, Representatives Mark Takano, Bill
Foster, Sean Caster, and Donald Beyer introduced the Office of Technology
Assessment Improvement and Enhancement Act, which will revive the Office
of Technology Assessment if passed.199 If the Office of Technology Assessment
is reconstituted, it could be part of a broader effort to educate both legislators
and the public on issues of reproductive genetic innovation.
2. Adapting the U.K.’s Public Consultation Methods to the U.S.’ Existing
Deliberative Process
The United Kingdom’s experience in legalizing mitochondrial transfer is
notable for its use of public participation and public education.200 While the
United Kingdom has a substantially more centralized system of regulating
ART than the United States, there are still some aspects of its regulatory system
that could be translated into an American societal discourse.201
comment rulemaking; however, there are other methods of rulemaking, that are even less
deliberative. See Lars Noah, Doubts About Direct Final Rulemaking, 51 ADMIN. L. REV. 401, 402 (1999)
(discussing “interim final” or “post-promulgation comment” rulemaking).
196. See generally Alexander M. Capron, Building the Next Bioethics Commission, 47 HASTINGS
CTR. REP. (SPECIAL REP.) S4 (2017); Jacob M. Appel, Opinion, Where’s Trump’s Bioethics
Commission?, Baltimore Sun, (May 31, 2019, 7:40 AM) https://www.baltimoresun.com/
opinion/op-ed/bs-ed-op-0603-bioethics-commission-20190531-story.html; SCIENCE, ETHICS,
AND GOVERNANCE, supra note 8, at 172.
197. Capron, supra note 196, at S7.
198. See David Malakoff, House Democrats Move to Resurrect Congress's Science Advisory Office, SCI.
INSIDER (Apr. 30, 2019), https://www.science.org/content/article/house-democrats-move-resurrectcongress-s-science-advisory-office. Princeton University maintains an archive of OTA publications.
See The OTA Legacy, PRINCETON U., https://www.princeton.edu/~ota/ (last visited Aug. 16, 2022).
199. Office of Technology Assessment Improvement and Enhancement Act, H.R. 4426,
116th Cong. (2019).
200. See, e.g., Lanphier, Urnov, Haecker, Werner & Smolenski, supra note 16, at 411;
Lewis, The American Democratic Deficit, supra note 65, at 145–47.
201. The United Kingdom has an “independent regulator,” the Human Fertilisation &
Embryology Authority, that regulates assisted reproductive technology. Steve P. Calandrillo
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The U.K.’s legalization of mitochondrial transfer was a lengthy twelveyear process that included multiple approaches to public consultation.202 In
the United Kingdom, the Parliament was responsible for passing regulations
to “allow techniques that alter the DNA of an egg or embryo to be used in
assisted conception, to prevent the transmission of serious mitochondrial
disease.”203 As part of the lead-up to the legalization of mitochondrial
transfer (under particularly limited circumstances), the Human Fertilisation
& Embryology Authority (HFEA), the “independent regulator” of ART in
the United Kingdom undertook multiple scientific reviews and a five-strand
public consultation.204 The HFEA-facilitated five-strand public consultation
& Chryssa V. Deliganis, In Vitro Fertilization and the Law: How Legal and Regulatory Neglect
Compromised a Medical Breakthrough, 57 ARIZ. L. REV. 311, 333 (2015); About Us, HUM.
FERTILISATION & EMBRYOLOGY AUTH. (June, 9, 2022), https://www.hfea.gov.uk/about-us/;
Human Fertilisation and Embryology Act, 1990, c. 37, § 5 (Eng.).
202. Senate Community Affairs References Committee, Parliament of Australia, Science of
Mitochondrial Donation and Related Matters (Report of 27 June 2018) 5–7,
https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Mi
tochondrialDonation/Report (providing a timeline of the U.K.’s legalization of mitochondrial
transfer, including the 2005 licensing of pronuclear transfer); Al Bredenoord & I. Hyun, The Road
to Mitochondrial Gene Transfer: Follow the Middle Lane, 23 MOLECULAR THERAPY 975 (2015).
203. HUM. FERTILISATION & EMBRYOLOGY AUTH., MITOCHONDRIA REPLACEMENT
CONSULTATION: ADVICE TO GOVERNMENT 9 (2013), https://www.hfea.gov.uk/media/2618
/mitochondria_replacement_consultation_-_advice_for_government.pdf [hereinafter ADVICE TO
GOVERNMENT]; see Joan Mahoney, Genome Mapping and Designer Babies: A Comparative Perspective, 79
UMKC L. REV. 309, 312 (2010) (discussing the scientific and social motivations for the 2008
Amendment to the 1990 Human Fertilisation and Embryology Act, the “enabling statute,” in
American parlance for the UK’s Human Fertilisation & Embryology Authority).
204. ADVICE TO GOVERNMENT, supra note 203, at 7. For the “three scientific reviews” of
mitochondrial transfer (and the 2014 addendum to the “further update in 2014”), see generally
HUM. FERTILISATION & EMBRYOLOGY AUTH., THIRD SCIENTIFIC REVIEW OF THE SAFETY AND
EFFICACY OF METHODS TO AVOID MITOCHONDRIAL DISEASE THROUGH ASSISTED
CONCEPTION: 2014 UPDATE (2014), https://www.hfea.gov.uk/media/2614/third_mitochondrial
_replacement_scientific_review.pdf; HUM. FERTILISATION & EMBRYOLOGY AUTH., SCIENTIFIC
REVIEW OF THE SAFETY AND EFFICACY OF METHODS TO AVOID MITOCHONDRIAL DISEASE
THROUGH ASSISTED CONCEPTION: UPDATE (2013), https://www.hfea.gov.uk/media/2612/
mito-annex_viii-science_review_update.pdf; HUM. FERTILISATION & EMBRYOLOGY AUTH.,
REVIEW OF THE SAFETY AND EFFICACY OF POLAR BODY TRANSFER TO AVOID MITOCHONDRIAL
DISEASE ADDENDUM TO ‘THIRD SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF METHODS
TO AVOID MITOCHONDRIAL DISEASE THROUGH ASSISTED CONCEPTION: 2014 UPDATE’ (2014),
https://www.hfea.gov.uk/media/2610/2014-10-07_-_polar_body_transfer_review_-_final.pdf;
HUM. FERTILISATION & EMBRYOLOGY AUTH., SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY
OF METHODS TO AVOID MITOCHONDRIAL DISEASE THROUGH ASSISTED CONCEPTION (2011),
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included a number of information gathering methods, including
“deliberative public workshops, . . . [a] public representative survey, . . . [an]
open consultation questionnaire, . . . open consultation meetings . . . and
patient focus groups.”205 While industry participants and patient groups
tend to be organized enough to “capture” the attention of regulatory
bodies like the FDA, especially its Advisory Committee Members, the
broader public, as noted in the next section on Citizens’ Juries, do not
interact with the agency employees as often. 206
Of the U.K.’s five methods of public consultation related to the approval
of mitochondrial transfer, deliberative public workshops could be especially
useful in the United States as the U.K.’s deliberative public workshops
focused on educating the public on the science of mitochondrial transfer, the
science and scope of mitochondrial disease, and discussing the social and
ethical issues related to techniques of mitochondrial transfer.207
Additionally, the U.K.’s open consultation meetings “involved a
combination of small group discussions around particular issues, whole
group debates, and discussion between and across the panel and the
floor.”208 In terms of structuring such debates, citizens’ juries, which are
the subject of the next section, could offer one method.
Similarly, the public meetings that are often structured in the context of
American agency meetings could be similar to the U.K.’s “open consultation
questionnaires.”209 In the “open consultation questionnaire” related to
mitochondrial transfer, interested members of the public considered information
posted on a public consultation website before submitting responses to seven
https://www.hfea.gov.uk/media/2613/scientific-review-of-the-safety-and-efficacy-of-methodsto-avoid-mitochondrial-disease-through-assisted-conception.pdf. See also HUM. FERTILISATION &
EMBRYOLOGY AUTH., SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF METHODS TO
AVOID MITOCHONDRIAL DISEASE THROUGH ASSISTED CONCEPTION: 2016 UPDATE 4–5 (2016),
https://www.hfea.gov.uk/media/2611/fourth_scientific_review_mitochondria_2016.pdf.
205. SARAH BARBER & PETER BORDER, MITOCHONDRIAL DONATION 13 (2015),
https://researchbriefings.files.parliament.uk/documents/SN06833/SN06833.pdf.
206. See Mendelson, supra, note 195, at 1357-58 (“Regulated entities tend to be heavily
represented in rulemaking, compared with regulatory beneficiaries—those who expect to benefit
from a regulatory program.”); Nicholas Bagley, The Procedure Fetish, 118 MICH. L. REV. 345, 389–
91, 394 (2019) (discussing “agency capture” and the “diffuse public interest”). For more FDAspecific analysis of these issues, see INST. OF MED., THE FUTURE OF DRUG SAFETY: PROMOTING
AND PROTECTING THE HEALTH OF THE PUBLIC 73–74 (Alina Baciu et al., eds., 2007); Fredrick H.
Degnan, An Introduction to FDA Advisory Committees, 45 FOOD, DRUG, COSMETIC L. J. 709 (1990);
Catherine M. Sharkey, States v. FDA, 83 GEO. WASH. L. REV. 1609, 1626 (2015).
207. ADVICE TO GOVERNMENT, supra note 203, at 10–11, 22.
208. Id. at 11.
209. See Sherman, supra note 191, at 416–17, 443 (2015).
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specific questions through the mail or online.210 In the United States, public
meetings (which are announced in the Federal Register and agency webpages)
are often used to increase public awareness of agency activities and facilitate
the submission of comments related to regulatory actions.211
Questions to be considered in the United States’ consultations can include
whether specific techniques of reproductive genetic innovation should be
permitted and a reminder of the demarcation between state and federal law
in issues such as recognizing the parentage of children conceived using ART
and reproductive genetic innovation. Further, a discussion of the bioethical
considerations that accompany reproductive genetic innovation could be
identified and discussed. Thus, if the FDA will continue to be the go-to
agency for issues of genetic modification, it could post documents related to
the scientific and ethical issues that accompany reproductive genetic
innovation on an easy to find website (as it did for each of the authorized
COVID-19 vaccines).212 Also, while the FDA is the first agency that many
scientists consider when addressing issues of reproductive genetic innovation,
the Centers for Disease Control and Prevention (CDC) could also play a role
in educating the public. The CDC is responsible for maintaining the ART
statistics required by the 1992 Fertility Clinic Success Rate Act, a statute that
is often criticized for its lack of enforcement mechanism.213 The CDC could
aid in the creation of shorter documents that provide the scientific background
that members of the public need to understand techniques of reproductive
genetic innovation, as it does with many other ailments. Creators of germline
gene editing view this education as imperative to the facilitation of a “rational

210. See ADVICE TO GOVERNMENT, supra note 203, at 10–11, 22.
211. See, e.g., Clarifying Current Roles and Responsibilities Described in the Coordinated
Framework for the Regulation of Biotechnology and Developing a Long-Term Strategy for
the Regulation of the Products of Biotechnology, 80 Fed. Reg. 60,414 (Nat’l Sci. Tech. Couns.
Oct. 6, 2015); Public Meeting Notice, 80 Fed. Reg. 62,538 (FDA Oct. 16, 2015).
212. See, e.g., Spikevax and Moderna COVID-19 Vaccine, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019covid-19/moderna-covid-19-vaccine (July 1, 2022); Comirnaty and Pfizer-BioNTech COVID-19
Vaccine, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/emergency-preparedness-andresponse/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine (last updated
July 1, 2022). Many scholars have recommended the creation of a separate administrative
agency to regulate assisted reproductive technology, similar to the UK’s Human Fertilisation
and Embryology Authority. Thus far, those recommendations have not been adopted. See,
e.g., Jamie King, Predicting Probability: Regulating the Future of Preimplantation Genetic Screening, 8
YALE J. HEALTH L., POL’Y & ETHICS 283, 321 (2008); Michelle Bayefsky, Who Should Regulate
Preimplantation Genetic Diagnosis in the United States?, 20 AMA J. ETHICS 1160, 1160–64 (2018).
213. See 42 U.S.C. § 263a-1 (2012).
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public discourse.”214 Thus, reproductive genetic innovation could provide an
opportunity for inter-agency cooperation to educate the public and to highlight
public views which may impact the regulatory process.215
3. Citizens’ Juries as a Method of Including the Public
While the definition of the term can vary, citizens’ juries are another form
of furthering “deliberative democracy.”216 Citizens’ juries use members of
the public as quasi-adjudicators who question expert witnesses, deliberate on
the issue presented, and then, instead of rendering a verdict, issue one or
more recommendations on that issue.217 Citizens’ juries, which are also
referred to as “citizens’ panels,” are modeled on the juries used in court cases,
although they aim to ascertain citizens’ views on scientific methods as
opposed to legal controversies.218 The “decisions made in citizens’ juries are
based on consensus, but do not have to be those of the majority.”219 Citizens’
juries have been used to ascertain public views on assorted innovations in
science, including nanotechnology, mitochondrial transfer, and genetically
modified foods.220 In the United States, a citizens’ jury was used for public
deliberations related to the 1993 Clinton Health Plan.221

214. See Jennifer A. Doudna & Emmanuelle Charpentier, The New Frontier of Genome
Engineering with CRISPR-Cas9, 346 SCIENCE 1258096-1, 1258096-7 (2014); Matthew C. Nisbet,
The Gene-Editing Conversation, 106 AM. SCIENTIST 15 (2018) (emphasizing the importance of
public participation in dialogue and sharing of knowledge).
215. See Doudna & Charpentier, supra note 214, at 1258096-7 (2014) (discussing the
importance of educating non-scientists to encourage and facilitate public discourse); INST.
MED., NAT’L ACADS., THE FUTURE OF THE PUB.’S HEALTH IN THE 21ST CENTURY 163 (2003).
216. Jennifer A. Whitty, Paul Burton, Elizabeth Kendall, Julie Ratcliffe, Andrew Wilson,
Peter Little Johns et al., Harnessing the Potential to Quantify Public Preferences for Healthcare Priorities
Through Citizens’ Juries, 3 INT’L J. HEALTH POL’Y AND MGMT. 57, 58 (2014).
217. Rogers-Hayden & Pidgeon, supra note 185, at 168.
218. Id.
219. Rachael Gooberman-Hill, Jeremy Horwood & Michael Calnan, Citizens’ Juries in Planning
Research Priorities: Process, Engagement and Outcome, 11 HEALTH EXPECTATIONS 272, 276 (2008).
220. See Rogers-Hayden & Pidgeon, supra note 184; Marchant & Askland, supra note 183, at 121.
221. See William Raspberry, A Citizen’s Look at Health Care, WASH. POST (Sept. 17, 1993),
https://www.washingtonpost.com/archive/opinions/1993/09/17/a-citizens-look-athealth-care/0928cae6-b00b-45ba-b9c5-b1f123c81031/ [hereinafter Raspberry, A Citizen’s
Look]; William Raspberry, ‘Citizens’ Juries’, WASH. POST (Jan 23, 1993), at A19 [hereinafter
Raspberry, Citizens’ Juries]; Ned Crosby & John C. Hottinger, The Citizens Jury Process, in THE
BOOK OF STATES 325 (Council of State Gov’ts, 2011 ed.).
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Such participatory methods have been used in Denmark, the United
Kingdom, and Australia. 222 While not the focus of much of the legal
literature on sensationalized innovations, citizens’ juries have been used
in the United States. 223 In the United States, citizens’ juries are often
associated with Ned Crosby, who used them a number of times in
different states before being involved with a Citizens’ Jury convened to
assess the Clinton Health Plan in 1993. 224
Citizens’ juries, like civil and criminal juries, should represent a cross-section
of society, although there is significant criticism that surrounds how citizens’
juries can be unrepresentative.225 Thus, citizens’ juries could involve the views
of individuals who are less likely to have made their views known, such as those
who lie between patient advocacy groups and those opposed to genetic
modification.226 In citizens’ juries, those who are members of special interest or
advocacy movements tend to be removed from the jury pool, similar to strikes
for cause.227 Other healthcare related citizens’ juries have also excluded
individuals employed as healthcare professionals or the government.228
The size of citizens’ juries can vary, as can the method of selecting
jurors.229 The Clinton Health Plan’s jury consisted of 24 “jurors” who were
222. Some have noted that citizens’ juries are based on a Danish model, whereas others
have referenced a German inspiration. See Rogers-Hayden & Pidgeon, supra note 185, at 168;
see also Dorit Rubinstein Reiss, Tailored Participation: Modernizing the APA Rulemaking Procedures,
12 N.Y.U. J. LEGIS. & PUB. POL'Y 321, 339 (2009) (discussing how Denmark has utilized
consensus conferences as a representative model for issues of science and technology);
Gooberman-Hill, Horwood & Calnan, supra note 219, at 274.
223. Rogers-Hayden & Pidgeon, supra note 185, at 168.
224. See supra note 223 and accompanying text; see also Huma Khan, Throwback to 1993?
What’s New About Democrats’ Health Care Plans, ABC NEWS (Sept. 25, 2009, 4:17 PM),
https://abcnews.go.com/Politics/HealthCare/health-care-reform-president-obama-path-billclinton/story?id=8675596 (recounting the similarities and differences between the Clinton
Health Plan and Obamacare/Affordable Care Act); Ben Smith, Obamacare vs. Clintoncare,
POLITICO (Mar. 23, 2010, 1:49 PM), https://www.politico.com/blogs/ben-smith/2010/03
/obamacare-vs-clintoncare-025991.
225. See Pickard, supra note 189, at 238; Jackie Street, Katherine Duszynski, Stephanie
Krawczyk & Annette Braunack-Mayer, The Use of Citizens’ Juries in Health Policy Decision-Making:
A Systematic Review, 109 SOC. SCI. & MED. 1, 5 (2014).
226. Gooberman-Hill, Horwood & Calnan, supra note 219 at 276.
227. Devidas Menon & Tania Stafinski, Engaging the Public in Priority-Setting for Health Technology
Assessment: Findings From a Citizens’ Jury, 11 HEALTH EXPECTATIONS 282, 284–85 (2008).
228. Tania Stafinski, Devidas Menon & Yutaka Yasui, Assessing the Impact of Deliberative Processes on
the Views of Participants: Is it ‘In One Ear and Out the Other’?, 17 HEALTH EXPECTATIONS 278, 279 (2012).
229. See id. (“Citizens’ juries bring together 12–16 individuals selected to be broadly
representative of their community. Over a two- to four-day period, they learn about a relevant
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selected through a process that was both random and “weighted so as to
reflect the ethnic, gender, age, income, geographic, educational and political
makeup of the electorate.”230 The 24 jurors were selected from a “random
pool of 2,000 American adults to be a microcosm of the nation in age, gender,
race, education (as an income indicator), geographic locale, 1992 presidential
preference, and source of healthcare financing. Jurors were paid their
expenses and a stipend of $600 for a week of meetings in Washington, DC.”231
Citizens’ juries in Germany, which are also referred to as “planning
cells” when used in an official governmental capacity, have used
moderators with a specific knowledge of the topic being discussed, but
specialized moderators are not always used for citizens’ juries. 232
Deliberations can be structured in many ways, including through
methods that involve strong direction by moderators or facilitators, or more
free form meetings reliant upon the direction of the jurors themselves
instead of moderators.233 The expertise of moderators also varies.234 Final
outcomes can be reported in different ways. For example, the 1993 Clinton
Health Plan citizens jury vote was “[u]nanimous (24-0) for reform of the
health care system[,] 19-5 against the Clinton plan[, u]nanimous (24-0) in
adopting 25 specific criteria for a health care reform plan to meet[,
u]nanimous (24-0) in believing the federal executive, legislative, and
judicial branches must live under the same plan adopted for the rest of
America[, and] 13-9 against rating any other plans.”235 The twenty-five
specific criteria that the jurors recommended included some aspects that
were addressed in the Patient Protection and Affordable Care Act such as
coverage for pre-existing conditions, prescriptions, and preventive care.236
issue, hear from expert ‘witnesses’ who offer different perspectives, engage in deliberations among
themselves and arrive at a common ground answer.”); Rachel Krinks, Elizabeth Kendall, Jennifer
A. Whitty & Paul A. Scuffham, Do Consumer Voices in Health-Care Citizens’ Juries Matter?, 19 HEALTH
EXPECTATIONS 1015, 1016 (2015) (noting that “jurors are invited to meet for (usually) 3-5 days”);
Gerry King, David J. Heaney, David Boddy, Catherine A. O’Donnell, Julia S. Clark & Francis S.
Mair, Exploring Public Perspectives on E-Health: Findings From Two Citizen Juries, 14 HEALTH
EXPECTATIONS 351, 353–54 (2010) (describing a one-day citizens jury).
230. See Raspberry, A Citizen’s Look, supra note 221; JEFFERSON CTR. FOR NEW
DEMOCRATIC PROCESSES, AM.’S TOUGH CHOICES: CITIZENS JURY ON HEALTH CARE
REFORM OCT. 10–14 (1993) [hereinafter AMERICA’S TOUGH CHOICES].
231. AMERICA’S TOUGH CHOICES, supra note 230, at 16.
232. Pickard, supra note 189, at 240–41.
233. See id. at 235, 240; Street, Duszynski, Krawczky & Braunack-Mayer, supra note 223, at 6–7.
234. Pickard, supra note 189, at 240 (“In Germany, moderators are required to have a
specific knowledge of the topic being discussed, whereas this is not the case in the USA.”).
235. See AMERICA’S TOUGH CHOICES, supra note 230, at 10–14.
236. Id.
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Interestingly, one commentator observed, in relation to the Clinton
Health Plan, that the citizens juries “are doing precisely what the House of
Representatives ought to be doing but can’t quite seem to.” 237 Applying
that same observation to the current situation in relation to germline gene
editing, a citizens’ jury could similarly be characterized as doing what
Congress should have done but has failed to do. The Clinton Health Plan
jury was “videotaped and edited down to a one-hour PBS presentation,”
which would allow for the dissemination of some of the expert information
used for the citizens’ jury deliberations to the general public. 238
Considering the role of citizens’ juries in the timeline of America’s
transition to increased health insurance availability, perhaps there will be
an evolution that begins with citizens juries on reproductive genetic
innovation, similar to the 1993 experience with the Clinton Health Plan
citizens’ jury. Additional Congressional subcommittee hearings would
occur along the way, some of which have already occurred in the context
of germline genetic modification. All of this could ultimately lead to larger
Congressional consideration and potentially legislation, as occurred with
the Patient Protection and Affordable Care Act. Even if contemporary
society is somewhere on this health insurance access timeline, there is also
a use for Congressional hearings. For example, during the debate on
cloning (which ultimately did not lead to substantive legislation), members
of Congress did convene hearings that involved FDA employees at least
staking out their positions on the regulation of cloning (albeit without
explanation). Ultimately, citizens’ juries aim to create a more informed
public which sometimes leads to jurors changing their views, but they do
not always cause jurors to change their views. 239 Citizens’ juries currently
do not directly influence the decisionmaking process, but this does not
mean that they could not in the future. 240 For example, in addition to
potentially changing the views of those on the juries, they could help
regulators identify biases in their own decisionmaking, and also provide
far more detail on potential ethical issues than comment submissions.

237. Raspberry, A Citizen’s Look, supra note 221.
238. Id. The deliberations of the Clinton Health Plan jury lasted over 60 hours. See
AMERICA’S TOUGH CHOICES, supra note 228 at 10–14.
239. See Gooberman-Hill, Horwood & Calnan, supra note 219, at 278; Stafinski, Menon,
& Yasui, supra note 228, at 286 (“All but one of the jurors thought their views had not changed
since the jury.”).
240. Pickard, supra note 189, at 241.
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4. Consensus Development Review: A Historical Method of Obtaining Expert
Consensus
While consensus methods are often associated with foreign countries,
consensus is actually not a foreign concept in the American health care
regulatory system. Not only was a method of consensus fostered in some
areas related to the Clinton Health Plan, but a “public trial,” referred to as
“Consensus Development Review,” was commenced before Medicare added
liver transplantation to its list of approved treatments thus rendering it no
longer “experimental.”241 After this Consensus Development Review, there
were Congressional hearings which discussed many issues including who
would pay for organ transplantation and how to procure donors.242
The Consensus Development Review that was used as part of the process
of adding liver transplantation to Medicare coverage was described as “[i]n
essence . . . a trial by jury of new forms of medical treatment.”243 As
conceived by the Surgeon General at the time, C. Everett Koop, it would
be a “[public trial in which] all evidence about liver transplantation would
be presented by those who advocated its acceptance and by those who
opposed it.”244 The “jury” to deliberate over the inclusion of liver
transplantation in Medicare’s covered services was to be fifteen people
“carefully selected to avoid bias for or against the proposition under
discussion. At the end, the jury would retire and render a verdict.” 245
Ultimately, the Consensus Development Conference on liver
transplantation took place from June twentieth to twenty-third, 1983 in
Bethesda, MD.246 Thirteen people (not the initial fifteen that were proposed)
comprised the Consensus Development Panel: ten had M.D.’s, two had
Ph.D.’s, and the one individual without an M.D. or a Ph.D. had a Master’s
of Science.247 Additionally, the “jury” used in the Consensus Development
Review differed from the type of jury used in a citizens jury because the jury
was composed of a number of medical experts as opposed to members of the

241. See STARZL, supra note 138, at 162, 252–54, 269.
242. Id. at 252.
243. Id.
244. Id. at 253; Biographical Overview, The C. Everett Koop Papers, NAT’L LIBR. OF MED.,
https://profiles.nlm.nih.gov/spotlight/qq/feature/biographical (last visited Aug. 16, 2022).
245. See STARZL, supra note 138, at 252–53.
246. Id. at 254.
247. See NIH Consensus Development Program, Liver Transplantation: National Institutes of Health
Consensus Development Conference Statement, NAT’L INSTS. OF HEALTH (1983), https://consensus.
nih.gov/1983/1983LiverTransplantation036html.htm.

ALR 74.3_LEWIS_481-538.DOCX (DO NOT DELETE)

2022]

NORMALIZING REPRODUCTIVE GENETIC INNOVATION

9/6/2022 11:13 AM

531

general public.248 Further, the Consensus statement was published in a
specialty journal, Hepatology. Nevertheless, this statement was critical to liver
transplantation being designated as a therapeutic treatment instead of as
“experimental.” The NIH’s Consensus Development Program was formally
retired in 2013. In a statement explaining why the program was retired, the
NIH noted that their Consensus Development Program “was created during
a time when few other organizations were providing evidence reviews. Today,
there are many other organizations that conduct such reviews, including
other federal agencies, academic institutions, and private organizations”
including assorted task forces and the Institute of Medicine.” 249
While the NIH believes that “other able parties” now serve the Consensus
Development Program’s role of “evidence review,” it may be worth reconstituting the program to commence a societal discourse on techniques
involving reproductive genetic innovation—even if that societal discourse
begins at the expert level, as opposed to the public level.250 If the Consensus
Development Program were re-constituted, then the public could benefit from
the involvement of an agency that is less involved in the regulatory process
than the FDA, albeit with a clear bias against germline gene editing.251
While there have been a number of International Summits devoted to
gene editing, there have been none devoted to cytoplasmic or
mitochondrial transfer. Therefore, a panel based on the Consensus
Development Panel of 1983 could be a forum for involved scientists and
physicians to create any consensus (if possible) and more easily
communicate that consensus to the public. While those who received
Untitled Letters from the FDA appeared at an Advisory Committee Meeting
in 2000, that meeting specifically foreclosed issues related to morality, ethics,
or society; this meeting would not have to do so.252 The Consensus
Development Panel’s Statement was largely technical and answered specific
questions related to the future of liver transplantation research in the United
248. See, e.g., id. (“After extensive review and consideration of all available data, this panel
concludes that liver transplantation is a therapeutic modality for end-stage liver disease that
deserves broader application. However, in order for liver transplantation to gain its full
therapeutic potential, the indications for and results of the procedure must be the object of
comprehensive, coordinated, and ongoing evaluation in the years ahead. This can best be
achieved by expansion of this technology to a limited number of centers where performance
of liver transplantation can be carried out under optimal conditions.”).
249. Retirement of the National Institutes of Health Consensus Development Program, NAT’L INSTS.
HEALTH, https://consensus.nih.gov (last visited Aug. 16, 2022).
250. Id.
251. See Collins, supra note 12 (providing the statements of Francis Collins on germline
gene editing).
252. MEETING #59 TRANSCRIPT, supra note 83, at 13.
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States and the establishment of institutional support.253 Nevertheless, the Panel
did conclude that liver transplantation was “a therapeutic modality for endstage
liver disease that deserves broader application[,]” thus recommending
expansion of liver transplantation innovation.254
Further, the Consensus Development Panel was not the only method of
publicly considering the “experimental” nature of liver transplants. Shortly
before the Consensus Development Panel, the Surgeon General and the
Assistant Secretary of the Department of Health and Human Services
testified before Congressman Albert Gore’s Investigations and Oversight
Subcommittee, Committee on Science and Technology. Throughout the
hearing Gore criticized federally funded health programs for withholding
reimbursement for liver transplants.255 He noted: “I don’t think the word
‘experimental’ can be fairly used to describe a procedure that has a 75-80%
success rate. The real issue is how quickly the bureaucracy represented at
the table can adjust to change of circumstance.” 256
One could argue that it is too early for a Consensus Development
Conference for certain forms of reproductive genetic innovation like
germline gene editing, but it is certainly not too early to do so for
mitochondrial and cytoplasmic transfer.
Moreover, contemporary
discussion of these reproductive genetic innovation techniques is often halted
by a statement about long-term effects.257 Yet, these same unknown longterm effects existed—and still do—with many currently approved
procedures, techniques, and medical products. 258 Similarly, the ethical
issues that accompany reproductive genetic innovation center on issues
related to (1) reproduction (and assisted reproduction) and (2) genetic
253. See NIH CONSENSUS DEVELOPMENT PANEL, National Institutes of Health Consensus
Development Conference Statement: Liver Transplantation–June 20-23, 1983, 4 HEPATOLOGY 107S, 107S
(1984). The Consensus Development Panel answered five “key” questions: “1. Are there groups of
patients for whom transplantation of the liver should be considered appropriate therapy? 2. What
is the outcome (current survival rates and complications) in different groups? 3. In a potential
candidate for transplantation, what are the principles guiding selection of the appropriate time for
surgery? 4. What are the skills, resources, and institutional support needed for liver transplantation?
5. What are the directions for future research?” Id.
254. Id. at 110S.
255 Gerald E. Markle & Daryl E. Chubin, Consensus Development in Biomedicine: The
Liver Transplant Controversy, 65 The Milbank Q. 1, 14 (1987).
256. Id.
257. See, e.g., Editorial, Gene Therapy Needs a Long-Term Approach, 27 NATURE MED. 563, 563
(2021); Lander et al., supra note 11, at 166 (explaining some of the criticisms and concerns behind
germline genome editing, such as the uncertainty behind its long-term effects, which need more study).
258. See Lewis, Is Germline Gene Editing Exceptional?, supra note 15, at 747–49, 810–13
(noting how ART is permissible in spite of its potential long-term effects).
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modification or substitution. The ethical issues that accompany assisted
reproduction and genetic innovation have existed for decades.
While this Section focuses on methods of soliciting public consultation
through the administrative law process, it is certainly notable that discussion
has not been occurring in Congress outside of the limited subcommittee
context.259 Moreover, even with the conversations that have occurred amongst
experts—in Congressional subcommittees, Federal Advisory Committee
Meetings, and public agency meetings—and behind agencies’ closed doors, a
national convening of the experts with the goal of producing the societal
consensus or discourse that scientists have requested has yet to occur.260
5. Agency and Media Outreach: Emphasizing and Addressing Safety and
Effectiveness
Outside of FDA authorization and approval, emphasizing safety and
effectiveness presents an avenue to reduce sensationalism. For example,
COVID-19 vaccines have been around for far less time than genetic
modification, including reproductive genetic innovation, and with far less
long-term or follow-up data than reproductive genetic innovation.261 Yet, in
addition to urgency, the safety and effectiveness of these vaccines has been
emphasized in data, media, and FDA presentations.262 As noted earlier, the
259. The Science and Ethics of Genetically Engineered Human DNA: Hearing Before the H. Subcomm.
on Rsch. & Tech. of the H. Comm. on Sci., Space, and Tech., 114th Cong. (2015).
260. See id.; see also I. Glenn Cohen & Eli Y. Adashi, The FDA is Prohibited from Going
Germline, 353 SCIENCE 545, 545 (2016) (explaining how conversation on germline genome
editing is repeatedly undermined by Congressional action).
261. See Damian Garde & Jonathan Saltzman, The Story of mRNA: How a Once-Dismissed Idea
Became a Leading Technology in the COVID Vaccine Race, STAT NEWS (Nov. 10, 2020),
https://www.statnews.com/2020/11/10/the-story-of-mrna-how-a-once-dismissed-idea-becamea-leading-technology-in-the-covid-vaccine-race/; Different Types of COVID-19 Vaccines: How They
Work, MAYO CLINIC (JULY 23, 2022), https://www.mayoclinic.org/diseases-conditions/coronavir
us/in-depth/different-types-of-covid-19-vaccines/art-20506465?p=1; Understanding mRNA COVID19 Vaccines, CTRS. FOR DISEASE CONTROL & PREVENTION, https://www.cdc.gov/coronavirus/
2019-ncov/vaccines/different-vaccines/mrna.html (July 15, 2022).
262. See Heidi Ledford, Six Months of COVID Vaccines: What 1.7 Billion Doses Have Taught
Scientists, 594 NATURE 164, 165-67 (June 4, 2021), https://www.nature.com/articles/d41586021-01505-x; Safety of COVID-19 Vaccines, CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html (Aug.
15, 2022); Tom Shimabukuro, COVID-19 Vaccine Safety Updates, VACCINE SAFETY TEAM, CDC
COVID-19 VACCINE TASK FORCE (June 10, 2021), https://www.fda.gov/media/150054/
download; Holly Yan, Covid Vaccine Myths Debunked: These Reasons for Not Getting a Shot Don’t Hold
Up. In Fact, They’ll Set the US Back, CNN (July 19, 2021, 2:38 PM), https://www.cnn
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recent experience with the rapid rollout and relatively high societal
acceptance of the COVID-19 vaccines provides lessons for a discourse
related to AARTs and heritable gene editing.263 In addition to FDA
pharmaceutical approvals, animal studies have been a part of the research
preceding the clinical use of organ transplantations and AARTs.264
Organ transplantation was developed in a way that involved many animal
trials.265 While animal trials are a typical component of pharmaceutical
development, they are less common in surgical innovation.266 Before bone
marrow transplantation was carried out in humans, experiments were
conducted on mice, dogs, and nonhuman primates.267 Kidney, heart, and
liver transplantation in humans were preceded by canine trials. 268
Interestingly, early organ transplantation efforts involved not only animal
trials, but also xenotransplantation, or interspecies transplantation. 269
.com/2021/07/19/health/covid-vaccine-myths-debunked/index.html; Michelle Roberts, How
Do We Know COVID Vaccines Are Safe?, BBC NEWS, https://www.bbc.com/news/health55056016 (last visited Aug. 16, 2022).
263. See Roberts, supra note 262; Sarah Kreps, Sandip Prasad, John S. Brownstein, Yulin
Hswen, Brian T. Garibaldi, Baobao Zhang et al., Factors Associated With US Adults’ Likelihood of
Accepting COVID-19 Vaccination, 3 JAMA NETWORK OPEN e2025594 (2020); Kimberly A.
Fisher, Sarah J. Bloomstone, Jeremy Walder, Sybil Crawford, Hassan Fouayzi & Kathleen
M. Mazor, Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults, 173 ANNALS
INTERNAL MED. 964 (2020); Peter G. Szilagyi, Kyla Thomas, Megha D. Shah, Nathalie
Vizueta, Yan Cui, Sitaram Vangala et al., National Trends in the US Public’s Likelihood of Getting a
COVID-19 Vaccine—April 1 to December 8, 2020, 325 J. AM. MED. ASS’N 396 (2021).
264. See supra notes 129 & 138 and accompanying text (describing how scientists used
animal clinical trials for research and pharmaceutical trials).
265. See supra Part IV.D.4.
266. See Jonathan J. Darrow, Jerry Avorn & Aaron S. Kesselheim, FDA Approval and
Regulation of Pharmaceuticals, 1983-2018, 323 J. AM. MED. ASS’N 164, 166 (2020) (noting the
different phases of pharmaceutical research when scientists would use animal tests); David
DeGrazia & Tom L. Beauchamp, Guest Editorial: Reassessing Animal Research Ethics, 24
CAMBRIDGE Q. HEALTHCARE ETHICS 385, 387 (2015).
267. See THOMAS’ HEMATOPOIETIC CELL TRANSPLANTATION 3–5 (Frederick R.
Appelbaum et al., eds., 4th ed. 2009); Frederick R. Appelbaum, Hematopoietic-Cell Transplantation
at 50, 357 NEW ENG. J. MED. 1472, 1473 (2007).
268. See Thomas Starzl, History of Clinical Transplantation, 24 WORLD J. SURGERY 759,
759–60 (2000); Norman Shumway, Thoracic Transplantation, 24 WORLD J. SURGERY 811, 811–
13 (2000); Gina Kolata, 2 American Transplant Pioneers Win Nobel Prize in Medicine, N.Y. TIMES,
Oct. 9, 1990, at C3; STARZL, supra note 138, at 99.
269. See, e.g., Starzl, supra note 268, at 760; Lawrence K. Altman, A Transplant Surgeon Who Fears
Surgery, N.Y. TIMES, July 7, 1992, at C1 (noting failed efforts to transplant baboon kidneys into
humans); Harold M. Schmeck Jr., Hope Gaining for Success in Human Liver Transplants, Surgeon Tells Parley,
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Thus, early transplantation included stories of surgeons transplanting
additional hearts onto dogs or attempting to transplant chimpanzee
hearts into humans.270 In the 1960s, some physicians participated in the
unsuccessful xenotransplantation of hearts and kidneys from chimpanzees
to humans.271 This sort of xenotransplantation does not characterize
forms of genetic modification in human reproduction.
Before IVF was achieved in humans, it was achieved in at least nine
animal species, although “[i]ronically, IVF . . . proved unusually difficult in
nonhuman primates.”272 Cytoplasmic transfer was also tested in mice and
primate models, before and after it was used on humans. 273
Mitochondrial transfer has similarly been tested on mice and non-human
primates.274 It has also been tested in human eggs and embryos although
not in pregnancies in the United States. 275 Before the U.K. legalized the
use of mitochondrial transfer in humans, the U.K.’s Chief Medical
Officer noted: “‘The only clinical tests you can do are either in rats, mice
and monkeys—and those have been done—or in humans and the mothers
now want to do this following those three scientific reviews.” 276
Similar to AARTs, heritable, specifically CRISPR-Cas9, and nonheritable gene editing, have been tested in mice, nonhuman primates, and

N.Y. TIMES, Oct. 11, 1964, at 41 (noting a then “successful” “chimpanzee-to-human kidney
transplant.”). For more on the history of xenotransplantation, see David K.C. Cooper, Burcin Ekser
& A. Joseph Tector, A Brief History of Clinical Xenotransplantation, 23 INTL. J. SURGERY 205 (2015).
270. D.K.C. Cooper, Experimental Development of Cardiac Transplantation, 4 BRITISH
M ED. J. 174, 180 (1968).
271. Id.; see also Robert M. Langer & Barry D. Kahan, 100 Years Ago: Ullmann’s Pioneering
Operation—Autotransplantation of the Kidney, 34 TRANSPLANT. PROC. 429, 429 (2002) (describing
a successful transplantation of a dog kidney into a goat).
272. See HENRY T. GREELY, THE END OF S EX AND THE FUTURE OF HUMAN R EPROD.
51 (Harvard Univ. Press 2016); see also Barry D. Bavister, Early History of In Vitro
Fertilization, 124 R EPROD. 181, 181 (2002).
273. See Henry E. Malter & Jacques Cohen, Ooplasmic Transfer: Animal Models Assist
Human Studies, 5 R EPROD. BIOMED. ONLINE 26, 28 (2002), https://www.rbmojournal
.com/article/S1472-6483(10)61593-3/pdf.
274. HERITABLE HUMAN GENOME EDITING, supra note 8, at 49, 117.
275. See id. at 49–50; U.S. FOOD & DRUG ADMIN., ADVISORY ON LEGAL RESTRICTIONS ON
THE USE OF MITOCHONDRIAL REPLACEMENT TECHNIQUES TO INTRODUCE DONOR
MITOCHONDRIA INTO REPRODUCTIVE CELLS INTENDED FOR TRANSFER INTO A HUMAN
RECIPIENT (2018), https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/
advisory-legal-restrictions-use-mitochondrial-replacement-techniques-introduce-donor-mitochondria.
276. Steve Connor, Chief Medical Officer Urges Lords to Legalise ‘Three-Parent’ IVF, INDEPENDENT
(Feb. 24, 2015, 1:05 AM), https://www.independent.co.uk/news/science/chief-medical-officerurges-lords-to-legalise-three-parent-ivf-10065833.html.
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human embryos.277 The technique was allegedly used in human births,
although that use has been the subject of widespread condemnation and
also some uncertainty as to whether it was actually used in humans as the
public has not been able to verify the births. 278
Thus, reproductive genetic innovation would be different than natural
reproduction yet the child would still be a part of the “common natural
human species genotype” although not necessarily “equally” kin to each
parent.279 This information should be emphasized at any public gathering,
in order to combat sensationalism and dystopian fears that often enter into
the conversation related to reproductive genetic innovation.
***
Public participation, especially through models like the U.K. model and
citizens’ juries, can make up for gaps in scientific understanding that might
contribute to sensational views based on a misunderstanding of certain
scientific processes.280 This Article focuses on federal administrative law
because the current site for the regulation of reproductive genetic innovation
appears to be the federal government, not states. Yet, states have often
fostered methods of considering controversial topics, as evidenced through
their convening of expert bodies like the Task Force on Life and Law in New

277. See SCIENCE, ETHICS, AND GOVERNANCE., supra note 8 at 55, 236; HERITABLE HUMAN
GENOME EDITING, supra note 8 at 89; Baltimore et al., supra note 11, at 36; Jon Cohen, China’s
CRISPR Push in Animals Promises Better Meat, Novel Therapies, and Pig Organs for People, SCIENCE, (July
31, 2019, 8:00 AM), https://www.sciencemag.org/news/2019/07/china-s-crispr-push-animals
-promises-better-meat-novel-therapies-and-pig-organs-people; Helen Shen, First Monkeys with
Customized Mutations Born, NATURE (Jan. 30, 2014), https://www.nature.com/news/firstmonkeys-with-customized-mutations-born-1.14611; Rob Stein, New U.S. Experiments Aim to Create
Gene-Edited Human Embryos, NPR (Feb. 1, 2019, 5:00 AM), https://www.npr.org/sections/health-s
hots/2019/02/01/689623550/new-u-s-experiments-aim-to-create-gene-edited-human-embryos.
278. See, e.g., Greely, supra note 44, at 113, 116. The truthfulness of the reports of the
“CRISPR’d babies” in China is unconfirmed. Id. at 116.
279. See Kass, supra note 57, at 21. While Kass’ article focused on making a case
against cloning, which is not a part of this Article’s analysis as the Author does not
consider cloning to be reproduction, Kass’ article is a part of a larger scholarship focusing
on limiting human interventions in reproduction.
280. See, e.g., Marchant & Askland, supra note 183, at 106–07 (“. . . on most science-laden
policy issues, the majority of the public is woefully ignorant of the subject, whether measured
by their own self-assessments or by more objective evaluations employing questionnaires or
survey” and “the ‘major finding’ of the National Science Foundation’s (NSF's) most recent
survey of public understanding of science and technology is that ‘Americans are highly
supportive of science and technology (S&T), but lack knowledge of them.’”).
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York and the California Advisory Committee on Human Cloning.281 The
current structure is one in which the regulatory system seems to be at an
impasse. Instead of facilitating research that would explore these concerns,
progress is halted in the United States, driven abroad, or driven
underground.282 Questions and clarifications related to the underlying
science of these procedures, safety and efficacy, and whether certain moral,
social, or political concerns should influence regulation could be explored in
a public consultation. Earlier sections have provided potential questions and
issues to consider in this consultation, which does not have to take place all
at once—an iterative approach may be warranted and more practical.283
CONCLUSION
This Article has introduced some potential means of increasing
participation in scientific decisionmaking, both in an effort to increase
transparency in administrative agency decisionmaking and in response
to scientists’ calls for a societal discourse.
Scientists continue to call for public and societal discourse related to
the topic of germline gene editing. When scientists and the public finally
do engage in conversation, it is worth reminding the public how similar
reproductive genetic innovation is to many other initially controversial
medical techniques and approved medical products, including organ
transplantation and somatic gene therapy.
This Article has also examined commonly accepted medical procedures
that are often accompanied with genetic changes, including whole organ and
bone marrow transplantation and gene therapy, that were initially treated as
controversial but are now viewed as commonplace.284 In addition to genetic
transfers, the Article has considered changes to the human immune system,
such as those that accompany vaccination.285 Emphasizing the similarities
between reproductive genetic innovation and other societally accepted
techniques such as organ transplantation, vaccination and IVF, could move
281. See New York State, Task Force on Life and the Law, https://www.health.ny.gov
/regulations/task_force/ (last updated Dec. 2017); Henry T. Greely, Cloning Californians –
Report of the California Advisory Committee on Human Cloning, 53 HASTINGS L. J. 1143–1203 (2002).
282. See Lewis, Subterranean Regulation, supra note 10, at 1259–62.
283. See Myrisha S. Lewis, Segmented Innovation in the Legalization of Mitochondrial Transfer: Lessons
from the U.S. Common Law Neighbors in Australia and the United Kingdom, 22 HOUS. J. HEALTH L. & POL’Y
(forthcoming 2022) (describing a potential incremental approach for the U.S. regulation of
mitochondrial transfer based on the experiences of the United Kingdom and Australia).
284. See, e.g., Carl Zimmer, DNA Double Take, N.Y. TIMES (Sept. 16, 2013),
https://www.nytimes.com/2013/09/17/science/dna-double-take.html.
285. See supra Part III.B.
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both the societal discourse and the regulatory framework forward by
situating gene-modifying techniques in larger context of medical practice.
While techniques involving reproductive genetic innovation are
controversial now, they share many commonalities previous practices,
namely organ transplantation and medical products, like gene therapy.
Broadly, AARTs and germline gene editing are part of the larger medical
field which involves counteracting natural processes to increase lifespan,
prevent disease, treat disease, or improve quality of life.
Normalizing reproductive genetic innovation means legalizing
reproductive genetic innovation. One step towards that normalization lies
in medicalizing those techniques within the discourse. The practice of
medicine involves human interventions that interrupt the “natural” process
of evolution.286 This Article has juxtaposed a number of long-standing
medical procedures, including some that are societally accepted as evidenced
through extensive insurance coverage, as well as others that remain
controversial and often unsubsidized through insurance coverage despite
being legal, such as IVF and egg freezing. While reproductive genetic
innovation does not currently seem to enjoy societal acceptance, if the
societal discourse and regulation of reproductive genetic innovation followed
the trajectory of previously controversial techniques that are now wellunderstood, it could at the very least enjoy a societal acceptance that leads to
increased research, innovation, and use by interested individuals.

286. Suter, supra note 15, at 960.

